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ABSTRACT 
 
Advances in prenatal diagnosis of genetic and congenital disorders with progressively more sensitive 
techniques may increase opportunities for consideration of prenatal gene therapy. There are a 
number of genetic and acquired disorders with peri or postnatal pulmonary manifestations. These 
include monogenetic diseases like cystic fibrosis or surfactant protein B deficiency that would 
presumably require long-term expression of the deficient or defective gene. However, there are also 
abnormalities of lung growth, such as congenital diaphragmatic hernia, or lung maturation, such as 
respiratory distress syndrome of prematurity, that could potentially benefit from strategies that 
achieve transient gene expression in specific pulmonary distributions. Considered an attractive target 
organ for fetal gene transfer, the developing lung, poses also some obstacles that would only be 
overcomed with the development of a variety of gene transfer methodologies: different types of 
vector, optimal site, route and timing of gene delivery. The fundament of this dissertation was to 
modulate lung growth/maturation by in utero gene transfer, aiming to unveil underlying mechanisms 
of normal and abnormal lung development.  
The first objective of this dissertation was to develop a new approach of gene transfer targeting the 
fetal lung in early stages of lung development. We developed a new method for direct injection of 
viral vectors into the rat fetal lung as early as the pseudoglandular phase of lung development using 
ultrasound guided microinjections. The pseudoglandular stage, characterized by intense branching 
morphogenesis, is the period of greatest overall growth of the airways and vasculature of the fetal 
lung and corresponds to a stage of immunologic immaturity. Therefore, gene transfer during this 
period has the potential to have major effects on key elements of lung growth with minimal potential 
for detrimental immune responses.  We aimed to compare two distinct types of vectors: an 
adenoviral vector and a lentiviral vector (equine infectious anemia virus-based), both expressing the 
enhanced green fluorescent protein reporter gene. This study confirmed that adenoviral vectors are 
more suitable when rapid, high-level and transient expression of the transgene is required; whereas 
lentiviral vectors are more appropriate to induce sustained and long-term expression.  One of the 
concerns in gene transfer protocols is to target a specific cellular compartment of a determined 
organ/system. Interestingly, interstitial compartment rather than epithelial cells were transduced in 
opposition to previous studies describing intrapulmonary, intraamniotic and intratracheal 
administrations of viral vectors. The observation of transduction of distinct cell populations within the 
lung with different routes of transduction raises the possibility of manipulating gene expression in 
viii                                                                                    Abstract 
specific and separate cell populations within the developing lung. We then decided to use this model 
system to perform an in vivo study of dynamic lung morphogenesis, involving a major player in 
branching morphogenesis, fibroblast growth factor 10 (FGF10). We observed that FGF10 
mesenchymal overexpression, on the fetal rat lung, resulted in the induction of consistent patterns of 
malformation, the appearance of which were developmental stage and location dependent. These 
malformations, in total, appear to closely recapitulate the morphology and histology of the entire 
spectrum of human Congenital Cystic Adenomatoid Malformation (CCAM). 
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RESUMO 
 
Os avanços no diagnóstico pré-natal de patologias genéticas e congénitas devido a técnicas 
progressivamente mais sensíveis, aumenta as oportunidades de aplicação de terapias génicas pré-
natais. Existem várias patologias pulmonares genéticas e adquiridas que se manifestam no período 
peri e pós-natal. Estas incluem doenças monogenéticas como a Fibrose Cística ou a Deficiência em 
Proteína Surfactante B, que requerem expressão a longo-termo do gene em causa. No entanto, 
existem também patologias relacionadas com crescimento pulmonar, como a Hérnia Diafragmática 
Congénita, ou maturação pulmonar, como o Síndrome Prematuro de Distress Respiratório, que 
podem beneficiar de estratégias de indução de expressão genica de forma transiente. Considerado 
um aliciante órgão-alvo para a terapia génica fetal, o pulmão fetal, coloca alguns obstáculos que só 
poderão ser ultrapassados com o desenvolvimento de várias metodologias: tipos de vectores, 
optimização de local, via e período de transferência génica. O fundamento desta dissertação foi 
modular crescimento/maturação pulmonar através de transferência génica in utero, pretendendo 
esclarecer os mecanismos moleculares reguladores no desenvolvimento pulmonar normal e 
anormal. 
 
O primeiro objectivo desta dissertação foi desenvolver uma nova abordagem de transferência 
génica para o pulmão nas fases inicias do seu desenvolvimento. Desenvolveu-se um novo método 
de injecção directa de vectores víricos no pulmão fetal de rato, durante a fase pseudoglandular, 
utilizando microinjecções guiadas por ultrasonografia. A fase pseudoglandular, caracterizada por 
intensa ramificação e crescimento global das vias aéreas e vasculatura do pulmão fetal, 
corresponde a um estadio de imaturidade imunológica. Sendo assim, a transferência génica durante 
este período terá, um maior efeito em elementos fundamentais do crescimento pulmonar com menor 
hipótese de desencadear respostas imunes. Dois tipos distintos de vectores víricos foram utilizados: 
um vector adenovírico e um vector lentivírico (Equine Infectious Anemia Virus), ambos expressam 
Enhanced Green Fluorescent Protein como gene marcador. Este estudo confirmou que os vectores 
adenovíricos são mais adequados quando se pretende obter expressão rápida, elevada e transiente 
do transgene; enquanto que os vectores lentivíricos induzem uma expressão sustentada no tempo.  
Uma das preocupações nos protocolos de transferência génica é atingir especificamente um 
determinado compartimento celular de um determinado órgão ou sistema. É de salientar que, 
ambos os vectores, transfectaram células do compartimento interstitial em oposição ao epitelial, 
descrito em estudos anteriores em que as vias de administração foram a intrapulmonar, a intra-
x                                                                                    Resumo 
amniótica e a intra-traqueal. A transdução de populações celulares distintas em estreita relação com 
o tipo de via de administração, aumenta as possibilidades de manipulação genética do pulmão em 
desenvolvimento. A etapa seguinte consiste em utilizar este modelo para efectuar um estudo in vivo 
da morfogénese pulmonar, manipulando um dos factores fundamentais no processo de ramificação, 
o fibroblast growth factor 10 (FGF10). A sobreexpressão mesenquimatosa de FGF10, no pulmão 
fetal de rato, resultou na indução de malformações císticas, cujo fenótipo era dependente do local e 
período em que se induzia essa mesma sobreexpressão. O fenótipo de todos os tipos de 
malformações induzidas, parece recapitular todo o espectro da Malformação Cística Adenomatoide 
Congénita do humano.  
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Normal Lung Development 
 
The bronchial tree of the human lung has more than 105 conducting and 107 respiratory airways 
arrayed in an intricate pattern crucial for oxygen flow [Weibel ER 1984; West GB, et al. 1997; Bejan 
A 2000; Mauroy B, et al. 2004]. Classical studies of lung structure raise the question of how the 
information required to generate a tree of such complexity is biologically encoded [Weibel ER and 
Gomez DM 1962; Metzger RJ and Krasnow MA 1999]. Lung development is a highly orchestrated 
process directed by mesenchymal-epithelial interactions which control and coordinate the temporal 
and spatial expression of multiple regulatory factors required for proper lung formation. Many 
endogenous and exogenous factors may disturb this delicate process leading to disorders of lung 
growth, maturation and function.  
Mammalian lung development initiates with the emergence of a small diverticulum, the 
laryngotracheal groove, from the ventral foregut endoderm into the splanchnic mesoderm [Chuang 
PT and McMahon AP 2003]. In humans, lung development begins at 3-4 weeks of gestation, 
whereas in mice and rats at 10 and 11.5 days post-conception (dpc), respectively (term mice 
gestation ~19 dpc; term rat gestation ~22 dpc). Larynx and trachea originate from the proximal 
region of the laryngotracheal groove, whereas the distal portion gives rise to bronchial buds, which in 
turn originate left and right lobar branches of the bronchial tree [Warburton D, et al. 2005]. The 
primary buds grow ventrally and caudally producing secondary bronchi. Pathways that control left-
right asymmetry determine the number of buds on the right and left sides, which is a species-specific 
feature. In mice and rats four lobes constitute the right lung and one lobe forms the left lung, 
whereas in humans the right lung is trilobed and the left is bilobed. As lung morphogenesis 
continues, each secondary bronchus undergoes dichotomous branching, a process responsible for 
the remarkable expansion of lung epithelium, until a functional lung with a particularly enhanced gas 
exchange surface area (0.1 micron thick by 70 square meters) is obtained [Chuang PT and 
McMahon AP 2003]. Three-dimensional branching pattern was carefully studied by Metzger et al 
[Metzger RJ, et al 2008]. They infer that the tree is generated by three geometrically simple local 
modes of branching: domain branching, planar bifurcation and orthogonal bifurcation, used in three 
different orders throughout the lung. Once left–right laterality of the lung is established, airway 
branching is driven by a ‘master’ branch generator, with three ‘slaves’ in the form of subroutines 
(series of discrete patterning events). Of these, one subroutine seems to instruct a periodicity clock, 
which times the appearance of subsequent branches; another determines the rotational orientation 
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of the branches around the axis of the parent airway; and the third mediates bifurcation. The 
molecular mechanism subjacent to this process was also investigated. The balance between 
fibroblast growth factor (FGF) expression, fibroblast growth factor receptor (FGFR) activation and 
Sprouty (Spry) 2-mediated inhibition of FGF signaling is possibly a central component, not only of the 
master branch generator, but also, of the periodicity-clock subroutine.  
 
 
Figure 1. Overview of lung development: stages and structure. 
 
Lung development comprises six different stages: the embryonic stage in which the lung primordium 
appears as a ventral diverticulum of the foregut, elongates caudally and branches for the first time 
giving rise to the main bronchi of the two lungs; the pseudoglandular stage, in which most of the 
branching morphogenesis takes place; the canalicular stage where the distal lung development and 
differentiation occurs concurrently with the pulmonary vascular network and surfactant synthesis; the 
saccular stage, when terminal sacs are formed in the peripheral airways with concomitant 
development of the capillary network and differentiation of type I and type II pneumocytes occurs; the 
alveolarization stage, the establishment of secondary septa results in alveolar formation; and the 
microvascular maturation, when double capillary layer of the immature alveolar septa is reduced to a 
single capillary layer [Perl AKT and Whitsett JA 1999; Roth-Kleiner M and Post M 2003]. To direct 
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this highly predetermined program, a multitude of controlling factors have been identified, namely 
transcription factors, growth factors and their receptors, extracellular matrix proteins and intercellular 
adhesion molecules. The role and the interplay between major molecular mediators will be reviewed 
in subsequent sections. Even if lung development is a continuum, in the following sections, 
molecular mediators and its interactions, structure and cell characterization, will be reviewed in close 
relation with each developmental stage. 
 
Table 1 - Stages of lung development: characteristic events and major molecular mediators.  
Stage Duration Characteristic events Major molecular mediators 
Embryonic 
Human 4-7 weeks 
 
Mouse 9.5-14.2 dpc 
 
Rat 11-12.5 dpc 
Outgrowth of trachea, right 
and left main bronchi and 
major airways 
HNF3ß, TTF1, RA, RAR, 
Shh, Ptch, Gli2, Gli3, FGF8, 
FGF10, HNF4, N-cadherin, 
activin-ß, activin-ßR IIA, 
lefty1/2, nodal, Pitx2 
Pseudoglandular 
Human 5-17 weeks 
 
Mouse 14.2-16.6 dpc 
 
Rat 12.5-18.5 dpc 
Formation of bronchial tree 
up to a preacinar level 
GATA6, N-myc, PDGF, 
PDGFR, EGF, EGFR, FGF, 
TGF-ß, Shh, Ptc, VEGF, 
BMP4, RA, RAR, Ghrelin, 
IL-6 
Canalicular 
Human 16-26 weeks 
 
Mouse 17.5-18.5 dpc 
 
Rat 18.5-19.5 dpc 
 
Formation of the pulmonary 
acinus and of the future air-
blood barrier; increase of 
capillary bed;  
epithelial differentiation;  
first appearance of surfactant 
GATA6, TTF1, HNF3ß, 
Mash1, VEGF 
Saccular 
Human 24-38 weeks 
 
Mouse 17.5-19 dpc 
 to 5 days 
 
Rat 19.5-22 dpc 
 to 7 days 
Formation of transitory air 
spaces 
HNF-3ß, TTF1, NF1, VEGF, 
VEGFR 
Alveolar 
Human 36 weeks       
to 2 years 
 
Mouse 5-30 days 
 
Rat 7-35 days 
Alveolarization by formation 
of secondary septa 
PDGF, PDGFR, FGF, 
FGFR, VEGF, VEGFR, 
angiopoietins, ephrins, RA, 
RAR 
Microvascular 
maturation 
 
Human birth  
to 2-3 years 
Thinning of interalveolar 
walls; fusion of the capillary 
bilayer to a single layered 
network 
VEGF, VEGFR, PDGF, 
PDGFR, angiopoietins, 
ephrins 
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EMBRYONIC STAGE 
In the human, early lung formation lasts from day 26 to 7 weeks after conception. The trachea and 
lungs originate from the endoderm layer, like the thyroid, esophagus, stomach, liver, pancreas and 
the intestines. Lung formation starts with an outgrowth of the ventral foregut, which gives rise to two 
primordial lung buds on either side of the esophagus. These buds invade the surrounding 
mesenchyme by dividing dichotomously forming the left and the right primordial lung. 
Early Lung Organogenesis 
Primitive foregut endoderm is driven to differentiate into respiratory epithelium by interactions of 
hepatocyte nuclear factor 3ß (HNF-3ß or foxa2), thyroid transcription factor 1 (TTF1 or Nkx2.1) and 
GATA family transcription factors at the level of gene transcription regulation, thus mediating not only 
surfactant protein genes but also other transcription factors and including smooth muscle genes 
[Zhou L, et al. 1996b; Keijzer R, et al. 2001].  
HNF-3ß is expressed in cells believed to be progenitors of respiratory epithelial cells. The genetic 
ablation of HNF-3ß in mice leads to embryonic death with absence of foregut and, therefore, 
absence of the lungs [Ang SL and Rossant J 1994]. Later in lung development, HNF-3ß-binding sites 
have been found in the promoter-enhancer elements of different genes expressed in differentiated 
respiratory epithelial cells, e.g. surfactant protein (SP) B, Clara cell-secretory protein (CCSP) and 
Clara cell marker 10 (CC10) [Stahlman MT, et al. 1998; Bingle CD and Gitlin JD 1993; Bohinski RJ, 
et al. 1994].  
 It was generally believed that TTF1 was important in endoderm specification because of colocalized 
expression with HNF3ß in the developing respiratory tract, HNF3ß regulation of TTF1 gene 
transcription and concerted transcriptional regulation via HNF3ß and TTF1. Mice lacking TTF1 
exhibit tracheoesophageal fistula and have hypoplastic lungs resulting in neonatal lethal phenotype. 
Moreover, early epithelial cell lineage determination is abrogated in these mutants [Kimura S, et al. 
1996]. Despite TTF1 proven roles in tracheoesophageal septation and lung development, no 
functional data is available for TTF1 role in endoderm specification [Zhou L, et al. 1996b; Keijzer R, 
et al. 2001]. 
GATA6, a member of the GATA family of zinc finger transcriptional factors, has been implicated in 
pulmonary endoderm specification and in epithelial and smooth muscle cell lineage diversity. Gata6 
is expressed in arterial smooth muscle, the fetal bronchi, urogenital ridge and bladder. GATA6 is 
 Normal Lung Development                                                   21 
 
 
essential for the differentiation of visceral endoderm via regulation of HNF4 [Morrisey EE, et al. 
1998].  
Another crucial player in this early stage is retinoic acid (RA). It binds to its receptor that 
translocates to the nucleus and influences gene transcription in target cells. Deletion of both RA 
receptor- and RA receptor-ß results in pulmonary agenesis, tracheoesophageal fistula and lobar 
agenesis [Mendelsohn C, et al. 1994]. 
 
Left-Right Asymmetry 
Left-right asymmetries are an integral part of the body plan and necessary for normal formation and 
localization of intrathoracic and intra-abdominal organs. By the 5th week after conception, the human 
lung is divided into five lobes, two on the left and three on the right, whereas mice and rats possess 
four lobes in the right lung and one lobe in the left lung. Several distinct, though conserved, 
mechanisms have been proposed during the establishment of left-right axis in vertebrates: sonic 
hedgehog (Shh) [Meyers EN and Martin GR 1999], fibroblast growth factor-8 (FGF8) [Boettger T, et 
al. 1999], HNF4 [Chen J, et al. 1998], N-cadherin [García-Castro MI, et al. 2000], activin-ß and its 
receptor IIA [Oh SP and Li E 1997]. All the involved pathways seem to join into modulation of the 
expression of genes belonging to the transforming growth factor-ß (TGF- ß) family, named lefty1, 
lefty2 and nodal. These signalling molecules are expressed at the left side of the lung.  
 
Epithelial-Mesenchymal Interactions 
The importance of mesenchymal-epithelial tissue interactions for early lung development has been 
known for several decades [Wessels NK 1970]. Each tissue compartment produces unique sets of 
growth factors and other signaling molecules, which signal in a paracrine manner between the 
epithelium and the mesenchyme. Their expression must be well coordinated as at some sites they 
need to enhance cell proliferation (at the edge of the growing lung buds), while at other sites they 
have to inhibit cell division (at branching points). Some of these players have been identified, 
including fibroblast growth factors (especially FGF10 and FGF7), transforming growth factor-ßs 
(TGF-ß), Shh, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet-
derived growth factor (PDGF) and bone morphogenic protein 4 (BMP-4), with their respective  
receptors and intracellular signaling molecules.  
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PSEUDOGLANDULAR STAGE  
During this period from 5 to 17 weeks in the human, the hierarchical pattern of pre acinar airways 
and blood vessels develops. By dichotomous branching the whole bronchial tree is formed. Further 
steps in lung development are differentiation of epithelial cells in a centrifugal manner with 
appearance of ciliated cells, goblet and basal cells and production of cartilage, which can already be 
found around the main bronchi before 10 weeks after conception [Burri PH 1999]. 
Branching Morphogenesis 
A highly ordered sequence of patterning events collectively referred to as branching morphogenesis 
generates the bronchial tree and defines the proximal-distal axis of the lung by the end of the 
pseudoglandular stage. This process results from reiterated combination of bud outgrowth, 
elongation and subdivision of terminal units [Hogan BLM 1999]. The initial branches are formed 
essentially by budding; in subsequent dichotomous subdivisions, extracellular matrix seems to play a 
role by accumulating at clefts, specific points that do not branch. The current model is depicted in 
Figure 2 and establishes that dynamic changing in relative activity of SHH, FGF10, and mSPRY2 in 
the branching process. SHH is high and FGF10 is correspondingly low where branching is not 
supposed to take place. In contrast, SHH is suppressed locally by patched (PTC) and hedgehog 
interacting protein (HIP), so that FGF10 is therefore high where a branch is supposed to occur. 
FGF10 in turn dynamically induces its inhibitor mSpry2 as branches lengthen. Thus, the net relative 
activities between SHH, FGF10, and mSPRY2 may determine FGF signal strength in the epithelium 
and hence the relative rate of bud outgrowth rate at a given point and hence interbranch length. As a 
bud begins to elongate toward a mesenchymal source of FGF10, mSpry2 begins to be expressed in 
the distal tip. During subsequent elongation, Fgf10 continues to be expressed in the distal 
mesenchyme and the level of mSpry2 gradually increases as the bud lengthens. When the bud 
finally approaches the pleura, the Fgf10 expression domain adjacent to the distal tip appears to thin 
out and some of it appears to be pushed laterally to lie between adjacent branch tips. At the time, 
mSpry2 expression in the distal tip is at its highest level, perhaps mediating bud outgrowth arrest. A 
tip-splitting event then occurs in which wingless (WNT) signaling drives fibronectin (FN) deposition 
between the branch tips, leading to epithelial cleft formation. Meanwhile, dickkopf-1 (DKK1) inhibits 
Wnt signaling away from the cleft, leading to lower levels of FN deposition where clefting does not 
occur. Of note is that mSpry2 expression is extinguished between the daughter bud tips, but 
continues to be expressed within the tips of the daughter bud epithelia. This cycle of interaction is 
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then repeated during subsequent branching events. Despite some controversy (see below), BMP4 is 
also an important factor that appears to enhance lung branch tip outgrowth according together with 
FGF10. FGF10 is shown stimulating BMP4 expression, whereas the ligand binding proteins gremlin 
(GRE) and chordin (CHO) exert negative modulation on BMP4. VEGF signaling appears to play 
necessary but complementary roles to accelerate this overall process [Warburton D, et al. 2005]. 
 
 
 
Figure 2. Current model for lung bud outgrowth, arrest and branching [from Warburton D, et al. 
2005]. 
 
 
 
 
 
 
24                                                              Normal Lung Development                                                    
 
                                     
Growth Factors and Signal interactions in Branching Morphogenesis 
In the following section transcription and growth factors with pivotal role in branching morphogenesis 
will be reviewed.   
FGF family  
There are 22 members of the fibroblast growth factor family in vertebrates, ranging in molecular 
mass from 17 to 34kDa and sharing 13-71% amino-acid identity [Ornitz DM and Itoh N 2001]. The 
defining features of the family are a high affinity for heparin and heparin-like glycosaminoglycans and 
a central core of 140 amino acids that is highly homologous between the family members.  
Many FGF have been implicated in multiple aspects of vertebrate development. FGF 1, 2, 7, 9, 10, 
and 18 play overlapping, yet distinct roles in the lung. In particular, FGF10 has been associated with 
instructive mesenchymal-epithelial interactions, such as those that occur during branching 
morphogenesis, whereas FGF9 and 18 appear to play a role in the mesenchyme and FGF1 and 7 
appear to play roles in mediating postnatal lung repair [Chailley-Heu B, et al. 2005].  
FGF10. In the developing lung, Fgf10 is expressed in the distal mesenchyme at sites where 
prospective epithelial buds will appear. Moreover, its dynamic pattern of expression and its ability to 
induce epithelial expansion and budding in organ cultures have led to the hypothesis that FGF10 
governs the directional outgrowth of lung buds during branching morphogenesis [Bellusci S, et al. 
1997]. Furthermore, FGF10 was shown to induce chemotaxis of the distal lung epithelium [Weaver 
M, et al. 2000; Park WY, et al. 1998]. The chemotaxis response of the lung endoderm to FGF10 
involves the coordinated movement of an entire epithelial tip, containing hundreds of cells, toward an 
FGF10 source. How this population of cells monitors the FGF gradient and which receptors trigger 
this effect remains unknown. Consistent with these observations, mice deficient for Fgf10 show 
multiple organ defects including lung agenesis [Min H, et al. 1998; Sekine K, et al. 1999; Ohuchi H, 
et al. 2000]. FGF10 also controls the differentiation of the epithelium by inducing SP-C expression 
and by up-regulating the expression of BMP4, a known regulator of lung epithelial differentiation 
[Weaver M, et al. 2000; Lebeche D, et al. 1999]. FGF10 is the main ligand for FGFR2b during the 
embryonic phase of development as evidenced by the remarkable similarity of phenotypes exhibited 
by embryos where these genes have been inactivated [Mailleux AA, et al. 2001; Sutherland D, et al. 
1996]. Thus, the paradigm proposed so far is that FGF10 expressed by the mesenchyme acts on the 
epithelium (which expresses FGFR1b and 2b). The biologic activities mediated through these two 
epithelial receptors are likely to be different, as FGF7 (acting mostly through FGFR2b) exhibits a 
different activity compared with FGF10 [Bellusci S, et al. 1997].  
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Fgf7, or keratinocyte growth factor, is expressed by mesenchymal pulmonary cells. FGF7 mediates 
epithelial-mesenchymal interactions by binding to FGFR2b. Fgf7 overexpression in pulmonary 
epithelium results in abnormal morphogenesis similar to cytadenomatoid malformation [Simonet WS, 
et al. 1995]. In mesenchyme-free cultures of murine fetal lungs, FGF7 induced cysts and patchy SpC 
expression [Cardoso WV, et al. 1997]. However, when administrated with competence factors, which 
alone did not influence pulmonary epithelium, FGF7 was able to induce reprogramming of tracheal 
epithelium to an alveolar type II pneumocyte phenotype [Deterding RR, et al. 1996]. Hence, FGF7 is 
necessary but not fundamental for the induction of distal lung epithelial differentiation. 
FGF9. During early pulmonary development, Fgf9 is expressed in endodermal epithelium and 
mesothelium, becoming later restricted to the mesothelium. Decreased branching and pulmonary 
hypoplasia result from targeting Fgf9, which originated diminished Fgf10 levels and consequently 
reduced mesenchymal proliferation [Colvin JS, et al. 1999; 2001]. It has been suggested that FGF9 
inhibits SHH-induced differentiation of peripheral pulmonary mesenchymal cells, thus maintaining a 
FGF10 progenitor population [Weaver M, et al. 2003]. 
FGFR. The cloning of the signal-transducing receptors for FGFs has revealed a tyrosine kinase gene 
family with at least four members. These four cell surface FGFRs bind members of the FGF family 
with varying affinity [Ornitz DM and Itoh N 2001]. FGFRs contain an extracellular ligand binding 
domain, a single transmembrane domain, and an intracellular tyrosine kinase domain. Following 
liagtion with FGFs, receptor tyrosine kinases (RTKs) activate the Ras/MAPK signalling pathway. 
Fgfr1, 2, and 3 encode two receptor isoforms (termed IIIb or IIIc) that are generated by alternative 
splicing, and each binds a specific repertoire of FGF ligands [Ornitz DM, et al. 1995]. FGFR2-IIIb 
(FGFR2b) is found mainly in epithelia and binds four known ligands (FGF1, FGF3, FGF7, and 
FGF10), which are primarily expressed in mesenchymal cells. Peters et al. [Peters K, et al. 1994] 
reported the first evidence of a key role for Fgfr2 during lung development. They showed that 
misexpression of a dominant negative form of Fgfr2 in the embryonic lung under the SP-C promoter 
led to a severe reduction in branching morphogenesis. Further evidence came from Fgfr2 
inactivation in the embryo. Whereas mice null for the Fgfr2 gene die early during embryogenesis, 
those that are null for the Fgfr2b isoform, but retain Fgfr2c, survive to birth [De Moerlooze L, et al. 
2000; Revest JM, et al. 2001]. Mice deficient for Fgfr2b show agenesis and dysgenesis of multiple 
organs, including the lungs, indicating that signaling through this receptor is critical for mesenchymal-
epithelial interactions during early organogenesis. This idea is supported by the finding that 
prenatally induced misexpression of a dominant negative FGFR, to abrogate FGF signaling, results 
in a hypoplastic, emphysematous lung phenotype [Hokuto I, et al. 2003]. In contrast, induced 
abrogation of FGF signaling postnatally did not produce any recognizable phenotype. 
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FGF signaling pathway. Upon reception of the extracellular signals (FGFs), RTK activate the 
Ras/MAPK signalling pathway. Stimulation of FGFR not only results in formation of the 
FRS2/Grb2/Sos complex, but the binding of a positive tyrosine phosphatase regulator, Shp2, to 
FRS2, which is required for full potentiation of MAP-kinase activation [Hadari YR, et al. 1998]. Many 
of the molecular components, such as Ras, GTPase, Raf kinase and MAPK are shared among 
different RTKs. Ras directly interacts with and activates Raf, which in turn phosphorylates and 
activates MEK, which then phosphorylates and activates the MAP kinases, including ERK1 and 
ERK2. ERK is an extracellular-signal-regulated kinase that can enter the nucleus and phosphorylate 
certain transcription factors (like ELK-1), leading to phosphorylation of cytoplasmic proteins followed 
by cell growth and differentiation [Schaeffer HJ and Weber MJ 1999] (Figure3). Members of the 
Sprouty, Sef, and mitogen-activated protein kinase phosphatase families are negative modulators of 
FGF signaling. These molecules affect the FGF signaling cascade at different levels to regulate the 
final output of the pathway. This multilayered regulation suggests that precise adjustment of FGF 
signaling is critical in development [Tsang M and Dawid IB 2004]. 
 
 
Sprouty family  
The first example of an FGF-inducible signaling antagonist arose from the discovery of the sprouty 
mutant during Drosophila trachea development, in which supernumerary tracheal sprouts arise. Spry 
is not only found downstream in the FGFR pathway, but also appears to be an inhibitor of other 
tyrosine kinase signaling pathways such as EGF and Torso [Tefft D, et al. 2002]. mSpry2 is localized 
to the distal tips of the embryonic lung epithelial branches and is down-regulated at sites of new bud 
formation [Sutherland D, et al. 1996]. On the other hand, mSpry4 is predominantly expressed 
throughout the distal mesenchyme of the embryonic lung. It has been suggested that both Spry2 and 
Spry4 share a common inhibitory mechanism. Both Sprouty translocate to membrane ruffles upon 
EGF stimulation. However, only SPRY2 was shown to associate with microtubules [Lim J, et al. 
2000]. Abrogation of mSpry2 expression stimulates murine lung branching morphogenesis and 
increased expression of specific lung epithelial maturation/differentiation markers [Tefft JD, et al. 
1999]. Conversely, overexpression of mSpry2 under the control of a SP-C promoter or by 
intratracheal microinjection of an adenovirus containing the mSpry2 cDNA, results in smaller lungs 
with a particular “moth-eaten” dysplastic appearance along the edges of the lobes, with decreased 
epithelial cell proliferation [Mailleux AA, et al. 2001]. Thus, not only is the function of Spry conserved 
during respiratory organogenesis, but also as seen by loss of function and gain of function studies, 
Spry plays a vital role in regulating lung branching morphogenesis. The investigation of mechanism 
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by which mSPRY2 negatively regulates FGF10 in mouse lung epithelial cells (MLE15), showed that 
mSPRY2 differentially binds to FGF downstream effector complexes [Tefft D, et al. 2002]. 
 
 
 
Figure 3. Schematic diagram of FGF signaling through Ras-MAPK pathway. The binding of the FGF to FGFR 
causes the autophosphorylation and activation of the receptor tyrosine kinases (RTK). The RTK binds to an 
adaptor protein Grb2 or Grb2-Sos complex via its docking protein Shp or FRS2. The Sos then activates the 
Ras, which in turn phosphorylates a series of MAP kinases (Raf, MEK, ERK). ERK enters nucleus 
phosphorylates and activates transcription factor like ELK-1, which regulates its targets. Sprouty, Sef, and 
mitogen-activated protein kinase phosphatase families are negative modulators of FGF signaling. 
 
 
Regulation of FGF signaling by Sprouty  
Early studies in chick limb bud demonstrated that overexpression of Spry resulted in a reduction in 
limb bud outgrowth, consistent with a decrease in FGF signaling [Minowada G, et al 1999]. This 
suggested a possible co-regulatory relationship between FGF signaling and Spry during 
development. In developing lung the native state mSPRY2 associates with Shp2 and Gap, which is a 
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GTPase-activating protein that hydrolyzes GTP to GDP. It is possible that in this state the binding of 
Shp2 to mSPRY2 regulates mSPRY2 activity. Upon FGFR activation, mSPRY2 disassociates from 
Shp2 and Gap and translocates to the plasma membrane, where it binds to both FRS2 and Grb2, 
thus blocking the formation of the FRS2/Grb2/Sos complex, resulting in a net reduction of MAP-
kinase activation. Thus, Sprouty would inhibit the formation of specific signaling complexes 
downstream tyrosine-kinase receptors resulting in modulation and co-ordination of cell growth and 
development during organogenesis. It is also known that Spry4 inhibits branching of endothelial cells 
as well as sprouting of small vessels in cultured mouse embryos. Endothelial cell proliferation and 
differentiation in response to FGF and VEGF are also inhibited by mSpry4, which acts by repressing 
ERK activation. Thus, Spry4 may negatively regulate angiogenesis [Lee MK, et al. 1998]. 
 
Shh, Patched and Hip 
Hedgehog signaling is essential for lung morphogenesis because Shh null produces profound 
hypoplasia of the lungs and failure of tracheoesophageal septation [Pepicelli CV, et al. 1998]. 
However, proximodistal differentiation of the endoderm is preserved in the Shh null mutant, at least 
in so far as expression of SP-C and CC10 genes are concerned. The expression of the SHH 
receptor, PTC, is also decreased in the absence of Shh as are glioblastoma transcription factors (Gli) 
1 and 3. On the other hand, lung-specific misexpression of Shh results in severe alveolar hypoplasia 
and a significant increase in interstitial tissue [Bellusci S, et al. 1997]. Fgf10 expression, which is 
highly spatially restricted in wild type, is not spatially restricted and is widespread in the mesenchyme 
in contact with the epithelium of the Shh null mutant mouse lung. Conversely, local suppression of 
SHH signaling by the induction of Ptc and Hip at branch tips may serve to facilitate FGF signaling 
locally, where branch outgrowth is stereotypically programmed to take place [Chuang PT and 
McMahon AP 1999]. Thus, temporospatial restriction of Fgf10 expression by SHH appears to be 
essential to initiate and maintain branching of lung. 
 
TGF-  family  
The TGF- superfamily can be divided into three subfamilies: TGF, BMP and activin [Massague J 
1998].  
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TGF-. There are three TGF- isoforms in mammals: TGF-1, 2, and 3. All of them have been 
detected in murine embryonic lungs [Millan FA, et al. 1991; McLennan IS, et al. 2000]. In early 
mouse embryonic lungs (E11.5), TGF-1 is expressed in the distal mesenchyme underlying 
branching points, whereas TGF-2 is localized in distal epithelium, and TGF-3 is expressed in 
proximal mesenchyme and mesothelium [Bragg AD, et al. 2001]. Mice lacking Tgfb1 develop 
normally but die within the first month or two of life of aggressive pulmonary inflammation. On the 
other hand, Tgfb2 null mutants die in utero of severe cardiac malformations, whereas Tgfb3 mutants 
die neonatally of lung dysplasia and cleft palate [Kaartinen V, et al. 1995; Buckley S, et al. 1996]. 
Embryonic lung organ and cell cultures reveal that TGF-2 plays a key role in branching 
morphogenesis, whereas TGF-3 plays a key role in regulating alveolar epithelial cell proliferation 
during the injury repair response [Zhou L, et al. 1996a; Zhao J, et al. 1999]. Thus, finely regulated 
and correct physiologic concentrations and temporospatial distribution of TGF-1, 2, and 3 are 
essential for normal lung morphogenesis and defense against lung inflammation.  
BMP. Several BMPs, including BMP3, 4, 5 and 7, are expressed during embryonic lung 
development. The expression of Bmp5 and Bmp7 has been detected in the mesenchyme and the 
endoderm of the developing embryonic lung respectively, while Bmp4 expression is restricted to the 
distal epithelial cells and the adjacent mesenchyme [King JA, et al. 1994; Bellusci S, et al. 1996; 
Takahashi H and Ikeda T 1996]. Most of the BMP signaling pathway components, such as BMP 
receptors: activin receptor-like kinase (ALK) 2, 3, and 6 and BMP specific receptor-regulated Smads 
(R-Smads), including Smad1, 5, and 8, are expressed in early mouse embryonic lung [Dewulf N, et 
al. 1995; Verschueren K, et al. 1995]. Overexpression of Bmp4, driven by the SP-C promoter in the 
distal endoderm of transgenic mice, causes abnormal lung morphogenesis, with cystic terminal sacs 
and inhibition of epithelial proliferation [Bellusci S, et al. 1996]. In contrast, SP-C promoter-driven 
overexpression of either the BMP antagonist Xnoggin or a dominant negative Alk6 BMP receptor to 
block BMP signaling, results in severely reduced distal epithelial cell phenotypes and increased 
proximal cell phenotypes in the lungs of transgenic mice [Weaver M, et al. 1999]. However, the exact 
roles of BMP4 in early mouse lung development remain controversial. In isolated E11.5 mouse lung 
endoderm cultured in Matrigel™ addition of exogenous BMP4 inhibited epithelial growth induced by 
the morphogen FGF10 [Weaver M, et al. 2000]. However, addition of BMP4 to intact embryonic lung 
explant culture stimulates lung branching morphogenesis [Shi W, et al. 2001]. Since conventional 
murine knockouts for BMP4 and BMP-specific Smads cause early embryonic lethality, their functions 
in lung development in vivo still need to be further defined. Interestingly, germ line mutations in BMP 
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type II receptors were found in familial primary pulmonary hypertension [Lane KB, et al. 2000]. 
Therefore, BMPs may play multiple roles in lung development.  
 
Wnt growth factor family  
Modulation of Wnt expression in embryonic and adult mouse lung suggests that Wnt pathways are 
important for cell fate decisions and differentiation of lung cell types. The Wnt growth factor family in 
the mouse is comprised of 19 different secreted ligands that interact with 10 known seven-span 
transmembrane receptors of the frizzled gene family and either one of two single-span 
transmembrane proteins, low-density-lipoprotein-receptor-related proteins 5 and 6 [Pinson KI, et al. 
2000; Tamai K, et al. 2000; Wehrli M, et al. 2000]. Historically, Wnt proteins have been grouped into 
two classes, canonical and noncanonical. Canonical Wnt bind to frizzled receptors, inhibiting 
glycogensynthase kinase-3b mediated phosphorylation of -catenin. Hypophosphorylated b-catenin 
accumulates in the cytoplasm, after which it translocates to the nucleus, where it heterodimerizes 
with members of the T cell factor (TCF) / Lymphoid enhancer factor (LEF) transcription factor family 
to activate the transcription of TCF/LEF target genes. Non-canonical Wnt activate other Wnt 
signaling pathways, such as the planar-cell-polarity -like pathway that guides cell movements during 
gastrulation [Heisenberg CP, et al. 2000]. Between E10.5 and 17.5, -catenin is localized in the 
cytoplasm and often also in the nucleus of the pulmonary epithelium and adjacent mesenchyme 
[DasGupta R and Fuchs E 1999]. Wnt ligands, frizzled receptors, and the Tcf/Lef1 transcription 
factors are expressed during early lung development. Studies of the expression pattern of several 
Wnt proteins (Wnt7b, Wnt2a, Wnt5a, Tcf1, Lef1, sFrp1, sFrp2) suggest that Wnt signaling can 
originate from the epithelium and mesenchyme and can target both tissues in an autocrine and/or 
paracrine fashion. Recent studies have related particular Wnt production to specific lung cell types: 
Wnt2 has been mapped predominantly to the mesenchyme, while Wnt7b was exclusively expressed 
in the lung epithelium [Pongracz JE and Stockley RA 2006]. Wnt signalling has also been reported to 
be important in the regulation of spatial and distal branching of the lung. While the importance of 
canonical Wnt signalling in lung development is well established, the role of non-canonical Wnt 
signalling is less clear. Wnt5a knock-out studies have shown, however, that non-canonical Wnt 
signalling is also important. In Wnt5a-/- animals the lung is morphologically smaller than in the wild 
type and has thickened mesenchyme. Furthermore, alveolar development is delayed, although not 
prevented. Lungs of Wnt5a knock-out animals also have increased expression of FGF10, Shh and 
BMP4 [Li C, et al. 2002; 2005] suggesting that the morphological changes might be related to 
dysregulation of other signalling pathways modulated by Wnt signalling.  
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DKK. Dickkopf (DKK) reveals FN as an important matrix target of Wnt signaling in lung 
morphogenesis. Recent experiments show that early embryonic mouse lung organ cultures treated 
with DKK1, a potent and specific diffusible inhibitor of Wnt action that is also endogenously secreted 
by the distal lung epithelium, display impaired branching, characterized by failed cleft formation and 
enlarged terminal buds. The DKK1-treated lung explants show reduced -smooth muscle actin (-
SMA) expression and defects in the formation of the pulmonary vascular network. These defects 
coincide with a pattern of decreased FN deposition and Pdgf-A expression. All of the DKK1-induced 
morphogenetic defects can be recapitulated by inhibition of FN with an antifibronectin antibody and 
conversely can be rescued by addition of exogenous FN [De Langhe S, et al. 2005]. This point out 
the importance of correct orientation of the extracellular matrix in response to growth factor signaling. 
It also suggests that fibronectin is a downstream target of Wnt signaling.  
 
EGF 
EGF is expressed in the distal epithelium and mesenchyme. Null mutation of Egfr results in a 50% 
reduction in branching and a neonatal lethal failure of lung maturation [Miettinen PJ, et al 1995; 
1997]. EGF was the first growth factor to be shown to exert an inductive role on chick trachea to 
induce ectopic branching [Goldin GV and Opperman LA 1980], as well as to accelerate branching 
through activation of its cognate EGFR tyrosine kinase in mouse embryonic lung in culture 
[Warburton D, et al. 1992; Seth R, et al. 1993]. In addition, null mutation of tumor necrosis factor 
(TNF)- converting enzyme, a cell surface protein sheddase that regulates release of active from 
latent forms of TNF-, amphiregulin, neuregulin-1, HB-EGF, and HerbB4, also causes a hypoplastic 
phenotype of lung in the perinatal stage and lethality in new born mice [Zhao J, et al. 2001].  
 
Proteoglycans 
Proteoglycans are deposited within the extracellular matrix during early embryonic lung branching 
morphogenesis and inhibition of proteoglycan synthesis or treatment with heparitinase severely 
affects branching [Smith CI, et al. 1990; Toriyama K, et al. 1997]. Both heparan sulfate and 
chondroitin sulfate proteoglycans are required for lung branching and in fact mediate the inductive 
effects of FGF10 binding to the epithelium [Izvolsky KI, et al. 2003; Shannon JM, et al. 2003].  
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VEGF 
Vascularization must perfectly match epithelial morphogenesis to ensure optimal gas exchange. 
Several VEGF isoforms are expressed in the developing epithelium, whereas their cognate receptors 
are expressed in and direct the emergence of developing vascular and lymphatic capillary networks 
within the mesenchyme. It is possible that VEGF signaling may lie downstream of FGF signaling, in 
as much as in vivo abrogation of FGF signaling severely affects both epithelial and endothelial 
morphogenesis. Vasculogenesis is initiated as soon as the lung evaginates from the foregut. The 
loss of even a single allele of Vegf leads to embryonic lethality between days E9.5 and E10.5 in the 
mouse [Miquerol L, et al. 1999]. VEGF is diffusely distributed in pulmonary epithelial and 
mesenchymal cells and is involved in controlling endothelial proliferation and the maintenance of 
vascular structure. VEGF is localized in the basement membrane of epithelial cells [Acarregui MJ, et 
al. 1999]. VEGF signals through the cognate receptors FLK-1 (fetal liver kinase- 1, or VEGFR2) and 
FLT-1 (fetal liver tyrosinase-1, or VEGFR1). VEGF signaling is responsible for the differentiation of 
embryonic mesenchymal cells into endothelial cells. In fact, epithelial cells of the airways are positive 
for VEGF, particularly at the budding regions of the distal airway [Brown KR, et al. 2001]. VEGF 
treated human lung explants show an increase of cellular proliferation in the distal airway epithelial 
cells with an upregulation of the mRNA expression of Sp-A  and Sp-C but not Sp-B [Brown KR, et al. 
2001]. 
 
 
Mechanical Forces 
 
In situ several physical forces are exerted on the developing lung including (a) fetal breathing 
movements, (b) peristaltic airway contractions and (c) lung fluid. Fetal breathing movements 
resulting from episodic diaphragmatic contractions have been observed in the human fetus as early 
as the first trimester and their incidence increases throughout the fetal period [Harding R 1997]. If 
they are inhibited either mechanically by bilateral thoracoplasty [Liggins GC, et al. 1981], 
neurosurgically by transecting the cervical cord above the phrenic motoneurons [Wigglesworth JS 
and Desai R 1979] or genetically in the myogenin null mouse lacking normal skeletal muscle fibers 
[Tseng BS, et al. 2000], lung hypoplasia results. Spontaneous peristaltic airway contractions are 
rhythmic narrowings of the airways by phasic contractions of the surrounding smooth muscle cells, 
producing a pulsatile distal-driven movement of lung liquid which might cause an expansion of the 
end lung buds, thereby stretching the epithelial layer lining the buds [Schittny JC, et al. 2000]. If the 
physiological circulation of lung fluid filling the air spaces is disturbed, lung development is disturbed. 
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Chronic deflation of one lung by drainage of lung liquid in the fetal sheep results in significant 
hypoplasia, while chronic overexpansion of the other lung by retention of fetal lung fluid results in 
hyperplasia [Moessinger AC, et al. 1990]. Taken together, these observations demonstrate the 
importance of mechanical forces for proper lung development. Mechanotransduction, i.e. the 
conversion of mechanical forces into biochemical signals, appears to be related with stimulation of 
gene expression of growth factors and their receptors via stress-induced activation of protein 
tyrosine kinases [Liu M and Post M 2000].  
 
Canalicular Stage 
The period between 16 and 26 weeks is manifested by ‘canalization’ of the primitive interstitium by 
capillaries leaning against the epithelium, marking the beginning of the future blood-air interface. The 
second landmark of this stage is the differentiation of the pulmonary epithelium into type II cells, the 
producers of surfactant, and subsequently type I cells, which contribute to the formation of a thinned 
prospective air-blood barrier.  
Epithelial Differentiation 
 
With proceeding of branching, numerous cell phenotypes with different morphology and gene 
expressions are established. Several transcription factors play a specific part in these differentiation 
processes. Mash-1 (mammalian achaete-scute homologue 1) is important for the pulmonary 
neuroendocrine cells, and Foxa2 (forkhead box A2), GATA-6 and TTF1 for the epithelial cells 
(ciliated cell, Clara cell, goblet cell, type II and type I cells). The absence of the respective 
transcription factors, shown in genetically altered mice, goes along with absence of the 
corresponding cell types [Borges M, et al. 1997; Tichelaar JW, et al. 1999].  
 
Saccular Stage 
Entering this stage at about 24 weeks in human pregnancy is crucial for extrauterine survival. The 
widening of the peripheral air spaces distal to the terminal bronchioles at the expense of intervening 
mesenchyme will allow for sufficient gas exchange. The prospective lung parenchyma is gaining in 
size by dichotomously branching of the terminal generations of the airway tree. Furthermore, during 
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this period, preparation for the real alveolarization starts by deposition of elastic fibers at the 
localizations where future secondary septa will form [Wasowicz M, et al. 1996].  
Surfactant    
 
Surfactant is comprised of about 90% lipids, 10% proteins and a lesser amount of carbohydrates 
[Weaver TE and Whitsett JA 1991], which are synthesized, stored, secreted and recycled or 
catabolised by alveolar type II cells. Epithelial cells differentiate into their descendants, including type 
II cells, during the canalicular stage under the influence of HNF-3ß and TTF1. TTF1 is normally 
expressed in postnatal type II cells but not in type I cells. In its absence as a result of gene targeting, 
the phenotype exhibits tracheoesophageal fistula, severe lung hypoplasia and no expression of 
surfactant proteins in its epithelium [Kimura S, et al. 1996]. Other transcription factors such as 
members of the nuclear factor I family (NF) also seem to influence SP-C gene expression [Bachurski 
CJ, et al. 1997]. In addition, the alveolar microenvironment has an influence on surfactant protein 
gene expression via signals provided by cell-cell or cell-extracellular matrix interactions and growth 
factors. In culture, isolated type II cells rapidly decrease their expression of SP-A, SP-B and SP-C, 
whereas surrounded by fetal lung fibroblasts and collagen they sustain the mRNA expression of 
these proteins [Shannon JM, et al. 1992]. When primary type II cell cultures are supplemented with 
keratinocyte growth factor (KGF or FGF7), the mRNA levels of SP-A, SP-B, SP-D are increased 
[Sugahara K, et al. 1995; Xu X, et al. 1998].  
 
Alveolar Stage 
At around 36 weeks of human gestation the stage of alveolarization starts with appearance of low 
ridges along both sides of the saccular walls. By further growth perpendicularly into the air space, 
they subdivide the saccules incompletely into smaller units, the alveoli. The trans-section of these 
newly formed interalveolar walls, named secondary septa, demonstrates a doubled capillary layer 
separated by a sheet of connective tissue. This immature structure does not yet correspond to the 
adult morphology with its thin interalveolar septa, in which a capillary monolayer occupies almost the 
whole space of the septum. Therefore, these structures will undergo more restructuring, called 
microvascular maturation [Burri PH 1999]. Among the variety of factors that participate in the control 
of budding of secondary septa, elastin appears as playing an essentitial role. Elastin deposition in 
the thickness of primary septa appears to have a spatially instructive role inasmuch as the specific 
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sites of elastic fiber formation correspond precisely to the location of future buds. New septa then 
extend that are composed of a double capillary layer, and elastin localizes at their tip. Other factors 
involved are FGFs (FGF2, FGF3, FGF4 and FGF7), PDGF (see below), collagenases, FN, 
proteoglycans [Bourbon J, et al. 2005].  
PDGF 
One of the leading factors controlling alveolarization is PDGF-A and its receptor PDGFR-. Mice 
lacking PDGF-A die either at early gestation or within the first weeks of life [Boström H, et al. 1996]. 
Animals, dying postnatally, have an emphysematous lung with areas of atelectasis without any signs 
of alveolarization [Boström H, et al. 2002]. They also lack alveolar smooth muscle cells, and as a 
consequence no elastin fibers can be demonstrated. Elastic fibers, however, are a prerequisite for 
secondary septa as mentioned above. Taken together, PDGF-A seems to prevent alveolarization by 
inhibition of alveolar smooth muscle cell formation. A double null mutant mouse has unveiled a 
couple of additional players influencing alveolarization, the FGFRs 3 and 4. If both receptors are 
unfunctional (FGFR-3–/– and FGFR-4–/–), the lungs show large dilated saccules, but no secondary 
septa and, therefore, no alveoli [Weinstein M, et al. 1998]. In contrast to the PDGF-A null mouse, 
alveolar smooth muscle cells are normally developed, suggesting another mechanism of action.  
 
VEGF 
VEGF has also been demonstrated to play a role in maintaining alveolar structure [Kasahara Y, et al. 
2000]. Lungs from newborn mice treated with antibodies to FLT-1 are reduced in size and display 
significant immaturity with a less complex alveolar pattern [Gerber HP, et al. 1999]. In contrast, the 
accumulation of VEGF in the alveoli appears to make transgenic VEGF mice more resistant to injury 
by hyperoxia [Corne J, et al. 2002; Compernolle V, et al. 2002]. VEGF is a target of hypoxia inducible 
transcription factor-2a (HIF-2a). Hif-2a–deficient newborn mice die from respiratory distress 
syndrome [Compernolle V, et al. 2002]. In Hif-2a null mice the expression of VEGF is dramatically 
reduced in alveolar epithelial type 2 cells. Moreover, addition of VEGF to early mouse embryonic 
lung explants markedly stimulates epithelial as well as vascular morphogenesis, playing an important 
role in matching the epithelial-capillary interface during lung morphogenesis. 
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Stage of Microvascular Maturation 
This final step in lung development takes place during the first 2–3 years after birth. The goal during 
this period is the restructuring of thick bilayered secondary septa to the mature interalveolar wall 
consisting of minimal interstitial tissue and a capillary monolayer. At the end of this developmental 
process, most of the alveolar capillary endothelium and flattened type I epithelium are in direct 
contact, which favors optimal gas exchange.  
Vascularization 
 
During the fetal period of lung development, important alterations of the three-dimensional structure 
of the capillary network lay the foundation for alveolarization. During the canalicular stage, there is a 
marked growth in capillary network which gets closer to the pulmonary epithelium. In the saccular 
stage, capillaries surround the future air spaces like sleeves. The intersaccular walls or primary 
septa contain a capillary bilayer. At the deposition site of elastic fibers within the primary septa crests 
of up-folded tissue of the intersaccular walls are developed. These crests increase in height and 
become the so-called secondary septa, which subdivide the saccules into smaller units, the alveoli. 
However, all these walls still contain a double capillary layer, which is suboptimal for gas exchange. 
It has been shown in rats that during the end of the third postnatal week (after the peak of 
alveolarization), the number of cells in the interstitium, especially of fibroblasts, are reduced 
predominantly by apoptosis [Schittny JC, et al. 1998]. This thinning of interstitial tissue may trigger 
the process by which the two capillary layers merge into one [Kimura S, et al. 1996]. Most of the 
molecular mechanisms are still unknown. Genetic analyses have demonstrated that cell-extracellular 
matrix and cell-cell interactions as well as growth factors and transcription factors are involved in 
vascular development. Members of the VEGF [Healy AM, et al. 2000], angiopoietin [Colen KL, et al. 
1999] and ephrin [Hall SM, et al. 2002] families appear to be key players in the control of pulmonary 
vascularization. 
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Cell and Gene Therapy 
 
Gene therapy can be defined as the use of genetic material to modify a patient's cells, by correcting 
an existing abnormality or providing cells with a new function, for the treatment of an inherited or 
acquired disease.  
Already in 1966, Tatum hypothesized that viruses could be used as effective tools for introducing 
genes [Kay MA, et al. 2001]. Also, shortly after, Kornberg suggested that it might be feasible to 
attach a gene to a harmless viral DNA and to treat monogenic deficiency diseases by putting the 
virus/gene complex into the patient’s cells [Kornberg A 1971]. However, the concept of gene therapy 
was introduced only in the late 1970s after the development of recombinant DNA technology.  In 
1987, Cline [Cline MJ 1987] still pointed out two major obstacles for the application of this technology 
to human marrow cells: extremely inefficient expression of a new gene in the host cell, and the lack 
of a convenient and clinically acceptable method of returning the genetically altered cells to the 
patient. Nevertheless, only in 1990 the first gene therapy protocol would be approved, and the era of 
clinical gene therapy officially launched [Wivel NA 2001]. Since then, gene therapy has been applied 
in clinical trials to treat a variety of diseases, including diseases that are caused by a small number 
of inherited genetic changes, such as cystic fibrosis or muscular dystrophy.  By administration of 
DNA rather than a drug, many different acquired diseases are currently being investigated as 
candidates for gene therapy, including cardiovascular disease, neurodegenerative disorders such as 
Parkinson's and infectious diseases such as viral hepatitis and HIV infection in addition to cancer 
(Table 1).  
 
 
Current applications and clinical trials 
The vast majority (83.9%) of gene therapy clinical trials to date have addressed cancer, 
cardiovascular disease and inherited monogenic diseases; the first two because of their enormous 
prevalence, impact and potentially fatal outcomes, the latter because the concept of replacing a well-
defined defective gene with its correctly functioning counterpart has an obvious appeal and rationale. 
Interestingly, trials targeting cardiovascular disease have outnumbered trials for monogenic disease 
since 2004, although the greatest successes of gene therapy to date have been achieved in the 
latter group. Is interesting to notice that the range of indications for which gene therapy trials have 
been approved so far has widened [Edelstein ML, et al. 2007].  
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Table 2 - Conditions for which human gene transfer trials have been approved [Edelstein ML, et al. 
2007]. 
 
Monogenic disorders Cancer 
  Cystic fibrosis Gynaecological 
  Severe combined immunodeficiency   breast, ovary, cervix 
  Alpha-1 antitrypsin deficiency   Nervous system 
  Haemophilia A and B   glioblastoma, leptomeningeal carcinomatosis, glioma, 
astrocytoma, neuroblastoma   Hunter syndrome 
  Huntington’s chorea Gastrointestinal 
  Duchenne muscular dystrophy   colon, colorectal, liver metastases, post-hepatitis liver 
cancer, pancreas   Becker muscular dystrophy 
  Canavan disease Genitourinary 
  Chronic granulomatous disease    prostate, renal 
  Familial hypercholesterolaemia Melanoma 
  Gaucher disease Head and neck 
  Fanconi’s anaemia   nasopharyngeal carcinoma 
  Purine nucleoside phosphorylase deficiency Lung 
  Ornithine transcarbamylase deficiency   adenocarcinoma, small cell, non small cell 
  Leukocyte adherence deficiency Mesothelioma 
  Gyrate atrophy Haematological 
  Fabry disease   leukaemia, lymphoma, multiple myeloma 
  Familial amyotrophic lateral sclerosis Sarcoma 
  Junctional epidermolysis bullosa Germ cell 
  Wiskott-Aldrich syndrome  
  Lipoprotein lipase deficiency Neurological diseases 
  Late infantile neuronal ceroid lipofuscinosis Alzheimer’s disease 
  RPE65 mutation (retinal disease) Carpal tunnel syndrome 
  Mucopolysaccharidosis Cubital tunnel syndrome 
 Diabetic neuropathy 
 Epilepsy 
Cardiovascular disease Multiple sclerosis 
  Peripheral vascular disease Myasthenia gravis 
  Intermittent claudication Parkinson’s disease 
  Critical limb ischaemia Peripheral neuropathy 
  Myocardial ischaemia  
  Coronary artery stenosis Ocular diseases 
  Stable and unstable angina Age-related macular degeneration 
  Venous ulcers Diabetic macular edema 
  Vascular complications of diabetes Glaucoma 
  Pulmonary hypertension Retinitis pigmentosa 
  Heart failure Superficial corneal opacity 
  
 Other diseases 
Infectious disease Inflammatory bowel disease 
HIV/AIDS Rheumatoid arthritis 
Tetanus Chronic renal disease 
Epstein-Barr virus Fractures 
Cytomegalovirus infection Erectile disfunction 
Adenovirus infection Anaemia of end stage renal disease 
Japanese encephalitis Parotid salivary hypofunction 
Hepatitis C Type I diabetes 
Hepatitis B Detrusor overactivity 
Influenza Graft versus host disease 
 
 
 Cell and Gene Therapy                                                     39 
 
 
 
Cancer 
Thus far, most of the clinical trials in gene therapy have been aimed at the treatment of cancer 
(66.5% of all gene therapy trials). Many different cancers have been targeted throughout the years, 
including lung, gynaecological, skin, urological, neurological and gastrointestinal tumors, as well as 
haematological malignancies and paediatric tumors. A range of different strategies has been applied 
to cancer gene therapy, from inserting tumor-suppressor genes (e.g. expression of the wild-type p53 
tumor-suppressor gene and Ref), to immunotherapy (e.g. intra-tumoral injection of vectors encoding 
cytokines or major histocompatibility molecules), to gene-directed enzyme pro-drug therapy 
[Edelstein ML, et al. 2007].  
 
Cardiovascular diseases 
Gene transfer for the therapeutic modulation of cardiovascular diseases is an expanding area of 
gene therapy. During the last decade several approaches have been designed for the treatment of 
hyperlipidemias, post-angioplasty restenosis, hypertension, and heart failure, and for protection of 
vascular by-pass grafts and promotion of therapeutic angiogenesis. Adenoviruses and adeno-
associated viruses (AAV) are currently the most efficient vectors for delivering therapeutic genes into 
the cardiovascular system. Gene transfer using local gene delivery techniques have been shown to 
be superior to less-targeted intra-arterial or intra-venous applications. To date, no gene therapy 
drugs have been approved for clinical use in cardiovascular applications. In preclinical studies of 
therapeutic angiogenesis, various growth factors such as VEGFs snd FGFs, have shown positive 
results; but also factors such as PDGF and HIF have been studied [Edelstein ML, et al. 2007]. Gene 
therapy also appears to have potential clinical applications in improving the patency of vascular 
grafts and in treating heart failure. The development of technologies that can ensure long-term, 
targeted, and regulated gene transfer, and a careful selection of target patient populations, will be 
very important for the progress of cardiovascular gene therapy in clinical applications [Rissanen TT 
and Ylä-Herttuala S 2007]. 
 
Inherited monogenic diseases  
The ultimate aim in treating monogenic diseases by gene therapy is the correction of the disorder by 
the stable transfer of the functioning gene into dividing cells (stem cells) to ensure the permanence 
of the correction. Cystic fibrosis (CF) is with no doubt the inherited monogenic disease that arouses 
more interest in gene therapy: one-third of the 109 trials for inherited monogenic disorders targeted 
this disease [Edelstein et al. 2007]. CF, is the most common inherited genetic disease in Europe and 
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the USA and the average life expectancy of patients with CF is less than 40 years, hence the interest 
in this disease as a prime target for gene therapy. The second most common group of inherited 
diseases targeted has been the severe combined immunodeficiency syndromes, representing about 
20% of the trials for monogenic diseases. This is a group of diseases in which gene therapy has 
shown lasting and clinically meaningful therapeutic benefit [Cavazzana-Calvo M, et al. 2000; Gaspar 
HB, et al. 2004; Ginn SL, et al. 2005; Gaspar HB, et al. 2006]. Another monogenic 
immunodeficiency, chronic granulomatous disease, has also been the target of a successful trial [Ott 
MG, et al. 2006]. Around 20 other monogenic diseases have been treated (see Table 1) and most of 
the trials have shown transient expression of the gene transferred, with detectable protein in some 
cases, but as yet no obvious therapeutic benefit.  
 
Neurological disorders 
Neurological disorders such as Parkinson's disease, Huntington's disease, amyotrophic lateral 
sclerosis, Alzheimer's disease, multiple sclerosis, stroke, and spinal cord injury are caused by a loss 
of neurons and glial cells in the brain or spinal cord. Cell replacement therapy and gene transfer to 
the diseased or injured brain have provided the basis for the development of potentially powerful new 
therapeutic strategies for a broad spectrum of human neurological diseases [Valori CF, et al. 2008; 
Kim SU and de Vellis J 2009]. To date, there are 20 registered phase I and II trials aimed at a variety 
of neurological diseases [Edelstein ML, et al. 2007].  
 
Ocular disorders  
Ocular gene therapy can be used for replacement of mutant genes or it can be used to achieve 
sustained local delivery of therapeutic proteins in the eye. The advantage of gene replacement is 
that it has the potential of correcting the primary defect and hence eliminates the source of a 
particular retinal disease [Campochiaro PA. 2002; 2007]. There are many potential applications of 
gene delivery in the eye including expression of antiangiogenic proteins in eyes of patients with 
neovascular diseases, expression of survival factors or anti-apoptotic proteins in eyes of patients 
with retinal degenerations, and expression of components of the antioxidant defense system in eyes 
of patients with diseases caused or exacerbated by oxidative stress [Nguyen QD, et al. CLEAR-AMD 
1 Study Group. 2006; Campochiaro PA, et al. 2006]. Ocular pathologies have been tackled with 12 
trials to date focused on conditions including retinitis pigmentosa, glaucoma and age-related macular 
degeneration [Edelstein ML, et al. 2007].  
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Pulmonary Gene Therapy 
Gene therapy is currently being evaluated for a wide range of acute and chronic lung diseases.  CF, 
SP-B deficiency and α1-antitrypsin deficiency are diseases that are associated with single gene 
defects and represent the obvious rationale for gene therapy of replacing the defective or absent 
gene. Chronic acquired respiratory disorders such as chronic obstructive pulmonary disease 
(COPD), asthma, or interstitial lung diseases are considered to be the product of a variety of 
endogenous (polygenic) and exogenous influences, and less obviously are associated with gene 
replacement therapy. These chronic inflammatory conditions likely arise from an imbalance between 
destructive and protective mechanisms, such that transient gene therapy, or gene therapeutics, can 
be useful to reconstitute a homeostatic balance by the short-term overexpression of protective genes 
or the suppression of damaging genes. Gene therapy is also considered a potential therapeutic 
approach for correction of pathological lung conditions, such as pulmonary hypertension. Kamezaki 
and co-workers demonstrated that extracellular super-oxide dismutase ameliorated pulmonary 
hypertension induced in the monocrotaline rat model [Kamezaki F, et al. 2008]. Recent advances in 
cancer biology have identified a number of tumor-associated antigens, and these can be targeted by 
cell-based and gene-based therapeutic vaccines for immunotherapy interventions in patients with 
lung cancer [Kolb M, et al. 2006]. To date, at least 90 gene therapy trials for lung conditions have 
been undertaken [Edelstein ML, et al. 2007] 
Cystic fibrosis. Since the discovery of the cystic fibrosis transmembrane receptor (CFTR) gene in 
1987, CF has been considered the major lung disease for intervention through gene therapy. 
However, 16 years after the first clinical trial for CF [Zabner J, et al. 1993] there is still no satisfactory 
treatment options. Several reasons can be considered for this failure. The ideal vector system has 
not yet been developed. Strategies to treat CF have employed vectors derived from adenovirus, AAV 
and oncoretroviruses [Engelhardt JF, et al. 1992; Zsengellér ZK, et al. 1999], but the utility of these 
vectors is limited by either host immune response, restricted packaging capacity, or low transduction 
efficiency, respectively. Even if adenoviral vectors, AAV vectors, and liposomes have been shown to 
transfer sufficient amounts of gene to the lung, but expression is always transient and the levels of 
expression are never high enough or lasting [Middleton PG and Alton EW 1998; Boucher RC 1999; 
Griesenbach U, et al. 2004]. The problems associated with repeat administration are yet unsolved. 
Harvey et al. delivered three doses of Ad-CFTR to the lungs of CF patients 3 months apart and 
demonstrated that after the third administration vector specific CFTR mRNA was no longer 
detectable [Harvey BG, et al. 1999]. Also, a phase 2B trial investigating the repeat administration of 
AAV-CFTR did not show significant improvement in lung function over time [Moss RB, et al. 2007]. 
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The answers to the questions of which pulmonary region and which cells are the best targets for CF 
gene therapy still must be elucidated. Clinical observations have shown that CF is initially localized in 
small airways, which are likely not within reach by the aerosols currently in use [Boucher RC 1999]. 
Mucous plugs and local infections may be real obstacles for gene transfer. The main target tissue for 
gene transfer is the superficial epithelium, which exhibits all ion transport functions of CFTR and is 
best accessible via the topical administration of vectors. However, the constitutively highest level of 
CFTR gene expression is localized in bronchial submucosal gland cells. These glands may be better 
accessed by the vasculature and systemic vector application [Boucher RC 1999; Griesenbach U, et 
al. 2004]. Another attempt to deliver gene vectors to these cells is to use adjuncts that can open tight 
junctions between surface epithelial cells (eg, sodium caprate) [Griesenbach U, et al. 2004]. The 
replacement of the CFTR gene in the airways alone will probably not compensate for all functional 
defects in CF patients. Data from the past few years have also suggested an impaired ability to clear 
bacterial airway infections, partly due to malfunctioning antimicrobial peptides (e.g., human -
defensin 1). Gene transfer could be used to deliver cytokines to the lung as an adjuvant therapy and 
thereby support the host response against bacteria. In pneumonia models, the survival of animals 
was improved by transient transgene expression of interleukin (IL)-12 and interferon (IFN)-, 
resulting in enhanced clearance of Klebsiella pneumoniae and Pseudomonas aeruginosa [Standiford 
TJ, et al.  2000]. This fact has important clinical relevance because of the increasing antibiotic 
resistance of P aeruginosa, which persistently colonizes airways in almost all CF patients.  
1-Antitrypsin deficiency is a second pulmonary disease with an underlying single gene defect and a 
target for gene therapy. It is still unclear whether the replacement of 1-antitrypsin in patients with 
emphysema affects the course of the disease [Abboud RT, et al. 2001]. Most attempts at gene 
replacement have seen unsuccessful because of the short-term expression and the high 
concentrations of protein required for therapeutic efficacy [Song S, et al. 1998]. However, using a 
nonhuman primate serotype of AAV, high levels of the persistent expression of 1-antitrypsin were 
seen in mice, even if there was preexisting immunity to human AAV [De BP, et al. 2006].  
Surfactant protein B deficiency is a rare disease caused by mutation in the Sp-B gene [Nogee LM, et 
al. 1994; Hamvas A, et al. 1995]. Because SP-B is normally made by type II epithelial cells in the 
lung, the onset of pulmonary function at birth causes affected newborns to develop progressive 
respiratory failure refractory to current therapeutic modalities. The SP-B gene mutation results in 
absent SP-B protein as well as perturbation of phospholipid, SP-A and C production in type II 
alveolar epithelial cells [Whitsett JA, et al. 1995]. Distal airspaces accumulate proteinaceous, 
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eosinophilic material, which is pathognomonic for congenital pulmonary alveolar proteinosis. 
Currently, the only curative therapeutic option for survival is lung transplantation. Prenatal gene 
therapy for SP-B deficiency could potentially prevent the fatal consequences of surfactant 
dysfunction. Prenatal diagnosis is currently possible. Although late gestational approaches have 
been successfully used [Hamvas A, et al. 1997; Pryhuber GS, et al. 1991], early gestational 
diagnosis via polymerase chain reaction-based techniques should facilitate prenatal treatment. Prior 
to birth the SP-B deficient lung is thought to develop normally, and SP-B-deficient mice show normal 
morphological lung development [Clark JC, et al. 1995]. The vector bearing SP-B should be 
delivered into the fetal lung with widespread transduction of type II cell precursors. The ultimate goal 
of in utero SP-B gene therapy is to correct the functional deficit even if in a temporary and/or partial 
way. This would prevent the onset of disease at birth and act as a bridge for lung transplantation. 
Primary Ciliary Dyskinesia is a heterogeneous genetic disease that is characterized by cilia 
dysfunction of the epithelial cells lining the respiratory tracts, resulting in recurrent respiratory tract 
infections. Despite lifelong physiological therapy and antibiotics, the lungs of affected patients are 
progressively destroyed, leading to respiratory insufficiency. There is no treatment as of today that 
could restore normal ciliary beating. Recessive mutations in Dynein Axonemal Intermediate chain 
type 1 (DNAI1) gene have been described in 10% of cases of Primary Ciliary Dyskinesia. Chinn et al. 
have recently published a report showing that it is feasible to transfer DNAI1 gene ex vivo to human 
airway epithelial cells with a lentiviral vector based on Simian Immunodeficiency Virus (SIV) 
pseudotyped with Vesicular Stomatitis Virus Glycoprotein (VSVG). More important, defective cells 
that had immotile cilia due to compound heterozygous mutations in the DNAI1 gene recovered ciliary 
beating after treatment with a lentivirus containing a normal DNAI1 gene. This was the first report on 
gene therapy focusing in Primary Ciliary Dyskinesia [Chhin B, et al. 2009]. 
COPD and Asthma Although there is no directed research in gene therapy for COPD, several 
possibilities are imaginable. Currently, the most accepted theory for the development of COPD is 
protease/ antiprotease imbalance similar to emphysema due to hereditary 1-antitrypsin deficiency. 
Some have shown that the pathogenesis of COPD involves not only elastases but also collagenases 
and gelatinases studies [Segura-Valdez L, et al. 2000]. Thus, the reestablishment of the balance by 
overexpressing antiprotease genes is theoretically beneficial, and the levels of antiproteases 
required should be lower, as in patients with 1-antitrypsin deficiency. Experimental models have 
suggested a role for 1-antitrypsin and secretory leukoprotease inhibitor in the treatment of this 
disorder [Tomee JF, et al. 1998; Rogers DF and Laurent GJ 1998]. Neutrophils are a major source of 
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proteases and reactive oxygen, and, because of their overabundance in COPD, gene therapy could 
also target adhesion molecules for neutrophils to reduce the influx of inflammatory cells into the lung 
parenchyma. The benchmark for all future treatments of asthma are inhaled corticosteroids and 
bronchodilators, which are an established therapy for the majority of asthmatic patients [Alton EW, et 
al. 1999]. Transient gene therapy could bring some benefit for asthmatic patients with severe 
disease who require high doses of systemic corticosteroids and for patients with corticosteroid-
resistant asthma. Another potential area for gene therapy might be in patients with steroid-resistant 
asthma. A study [Mathieu M, et al. 1999] has shown that the transfer of the glucocorticoid receptor 
gene in vitro mediated the inhibition of NF-B activities even in absence of exgenous corticosteroids, 
and the authors suggested  hat this approach could restore corticosteroid sensitivity  in patients.  
Lung Cancer This is an area of development with gene based vaccines and immunotherapy of lung 
cancers. Here, access to the tumor is limited, and the intent is to stimulate the host immune 
response against unknown antigenic epitopes expressed by cancer cells in an effort to control cell 
growth and metastases. A nonviral vector expressing IL-12 was administered through intranasal 
instillation in mice to inhibit lung metastatic growth of osteosarcoma [Duan X, et al. 2006], while a 
granulocyte-macrophage colony-stimulating factor, gene-modified, autologous tumor cell vaccine 
elicited vaccine-induced immune activation in patients with advanced-stage non-small cell lung 
cancer [Nemunaitis J, et al. 2006]. Adenoviral vectors have been used to deliver intrapulmonary IFN-
 to mice bearing an orthotopic graft of bronchogenic adenocarcinoma of the lung [Wilderman MJ, et 
al. 2005] and to deliver suicide genes (herpes simplex virus thymidine kinase) to the pleural space in 
patients with malignant pleural mesothelioma, eliciting some surprising clinical responses [Sterman 
DH, et al. 2005]. These are examples of developments that will increase as the efficacy and 
specificity of gene transfer to the lung increases [Rüttinger D, et al. 2006]. 
   
 
   
 Cell and Gene Therapy                                                     45 
 
 
Gene Therapy Methods 
In gene therapy studies have to consider many different issues, ranging from the medical aspects of 
a specific disease (type of genetic modification, cellular target), to the basic laboratory work 
concerning the appropriate gene construct design (type of vector, size of transgene, type of 
promoter, reporter and, eventually, type of envelope) and delivery systems (administration route, 
timing, optimal titer) [Lazo PA and Yunta M 2000]. Each of these aspects will be discussed further on 
with special focus on pulmonary gene transfer. 
Types of vectors 
 
Several viral and non-viral gene transfer agents have been evaluated for a range of conditions in 
animal models and in the clinic (Figure 4). Both physical and immunological barriers exist, and these 
must be tackled. Although encouraging progress has been made, particularly for lung cancer and 
CF, all these studies are plagued by low levels of gene transfer. Given the diversity of disease 
targets that are potentially amenable to gene transfer, it has become clear that there can be no 
single vector that is suitable for all applications. It is unlikely that a single vector would be optimal for 
all lung gene therapy applications. Perhaps the only characteristics that are required by all vectors 
are (a) the abilities to be reproducibly and stably propagated and purified to high titers, (b) to mediate 
targeted delivery to the tissue or organ of interest without widespread dissemination, and (c) to 
mediate gene delivery and transgene expression without inducing harmful side effects [Thomas CE, 
et al. 2003]. Ultimately, all disease targets will benefit from an improved understanding of the biology 
of vector delivery, uptake and expression. Improvements in vector design will gather rewards in the 
clinic [Gill DR, et al. 2004].  
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Figure 4 – Vectors used in gene therapy clinical targets [Edelstein ML, et al. 2007].  
 
Viral vectors  
 
Viruses are highly evolved biological machines that efficiently gain access to host cells and exploit 
the cellular machinery to facilitate their replication. Ideal virus-based vectors for most gene-therapy 
applications harness the viral infection pathway but avoid the subsequent expression of viral genes 
that leads to replication and toxicity. This is achieved by deleting all, or some, of the coding regions 
from the viral genome, but leaving intact those sequences (usually the terminal repeat sequences) 
that are required in cis for functions such as packaging the vector genome into the virus capsid or 
the integration of vector DNA into the host chromatin. The expression cassette of choice is then 
cloned into the viral backbone in place of those sequences that were deleted. The deleted genes 
encoding proteins that are involved in replication or capsid/envelope proteins are included in a 
separate packaging construct to provide helper functions in trans. The packaging cells into which the 
vector genome and packaging construct are co-transfected then produce the recombinant vector 
particles [Thomas CE, et al. 2003]. After production in a packaging cell line, the recombinant vector 
particles are purified and quantified. Purification strategies have traditionally relied on the separation 
of vector particles from cellular components by density gradient centrifugation (usually a caesium 
chloride gradient); however, this process is laborious, difficult to scale up for industrial purposes and 
can sometimes damage the vector particles and reduce the infectious titre of the vector stock. 
Advances in column-chromatographic methods for the purification of several classes of vector have 
alleviated these concerns [Clark KR, et al. 1999; Green AP, et al. 2002] and most of the main 
classes of vector that are described here are now able to be grown and purified to the high titers 
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required for administration to humans. The number of different viruses that are under development 
as gene-therapy vectors is steadily increasing, but there are, at present, five main classes of 
clinically applicable viral vector that are derived from adenoviruses, AAVs, oncoretroviruses, 
lentiviruses, parainfluenza viruses. 
 
Adenoviral vectors 
Adenovirus has been one of the most extensively studied recombinant viral systems for gene 
transfer to the lung. Adenovirus has a large, complex linear 36-kb DNA genome and is attractive for 
gene therapy to the lung because it efficiently transduces dividing and non-dividing cells of the 
airway [Kovesdi I, et al. 1997; Cao H, et al. 2004]. Their viral coat proteins are organized in an 
icosohedral, non-enveloped capsid. The adenoviral genes are divided into early and late classes, 
based on the time of their expression during the viral lifecycle. Among the DNA regions for early 
RNA transcripts, E1a and E1b encode proteins for trans-activating other viral genes or regulating the 
host cell cycle, E2 for viral DNA replication, E3 for modulating host immune responses, and E4 for 
inhibiting host cell apoptosis [Parks RJ 2000]. Because the vector genomes persist as episome and 
do not integrate, repetitive dosing would be required in any gene therapy protocol for inherited 
genetic deficiencies. Numerous regulator and structural viral genes have made this virus one of the 
more complex vector systems to engineer in a fashion that does not invoke a cellular immune 
response.  
The first generation adenoviral vectors (FGAd) have been the most extensively used vector for 
pulmonary gene transfer, namely with the goal of treating CF. FGAd vectors are characterized by E1 
viral gene deletion that inhibit, but do not completely prevent, viral gene expression and replication. 
Transgene sequences are normally inserted into the E1-deleted region but can also be inserted into 
the E3 region. In most FGAd, the E3 region has also been deleted to make room for the insertion of 
a transgene cassette. Although once thought to be an ideal vector for CF gene therapy, more than a 
decade of research has revealed a number of serious shortcomings and the enthusiasm for FGAd as 
diminished for several reasons. First, pulmonary delivery of FGAd in small animals, large animals, 
and humans is inefficient [Grubb BR, et al. 1994; Harvey BG, et al. 1999; Zuckerman JB, et al. 1999; 
Joseph PM, et al. 2001; Perricone MA, et al. 2001]. It was discovered that the cellular receptor for 
adenovirus, the Coxsackie Adenovirus Receptor (CAR), resided on the basolateral surface of the 
airway epithelial cells and that the tight junctions prevented vector–receptor interactions required for 
transduction [Pickles RJ, et al. 2000]. Even if previous studies in mice and cotton rats have 
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demonstrated efficient gene transfer to the airway for both CFTR [Rosenfeld MA, et al. 1992; Yang 
Y, et al. 1994] and -1 antitrypsin gene [Rosenfeld MA, et al. 1991], comparison with human models 
has demonstrated that transduction from the apical surface of human airway cells is much less 
efficient than that found in rodents [Engelhardt JF, et al. 1993]. In part, this difference is thought to be 
the result of species-specific differences in the abundance of CAR [Bergelson JM, et al. 1997], on 
the apical surface of airway cells [Walters RW, et al. 1999]. V5 integrin, an identified co-receptor for 
adenovirus type-2, is also localized to the basolateral membrane of human airway epithelium and 
may be responsible for the low efficiency of recombinant adenovirus infection in polarized airway 
epithelia [Goldman MJ and Wilson JM. 1995; Pickles RJ, et al. 1998]. A significant finding was that 
transient disruption of the tight junctions could significantly increase the efficiency of transduction 
thus dramatically decreasing the vector dose required to achieve therapeutic levels of transduction. 
Various strategies have been proposed to improve adenoviral entry into airway epithelia including 
calcium phosphate coprecipitates [Lee JH, et al. 1999], EGTA [Chu Q, et al. 2001], EDTA [Wang G, 
et al. 2000], polycations [Kaplan JM, et al. 1998], polidocanol [Parsons DW, et al. 1998], sodium 
caprate [Johnson LG, et al. 2003], L-a-lysophosphatidylcholine [Koehler DR, et al. 2005], and other 
agents. A controversial issue is whether such tight junction openers can be used clinically in 
diseases like CF, given the heavy bacterial colonization in the lung and the attendant risk of systemic 
invasion. The second main reason that restrained the enthusiasm regarding adenoviral vectors is 
that gene expression from first-generation vectors is also accompanied by an intense cellular 
immune response to virally expressed genes [Kovesdi I, et al. 1997]. This has been attributed to 
expression of the viral genes present in the vector backbone of FGAds, which is directly cytotoxic 
and also provokes an adaptive cellular immune response against the transduced cells consequently 
resulting in transient transgene expression and longterm, chronic toxicity (through major 
histocompatibility complex class I-restricted antigen presentation and subsequent activation of CD4C 
and CD8C cytotoxic T-lymphocytes) [Yang Y, et al. 1995a; Dai Y, et al. 1995; Morral N, et al. 1997]. 
Second-generation vectors have been generated in an attempt to reduce this cellular immune 
response [Yeh P and Perricaudet M 1997; O’Neal WK, et al. 1998]. In such vectors, deletions or 
temperature-sensitive mutants of E2a, E2b, and/or E4 have been tested with some success 
[Engelhardt JF, et al. 1994; Lusky M, et al. 1998]. Complex complementing cell lines that express E2 
and/or E4 are needed to propagate second-generation viruses [Gorziglia MI, et al. 1999]. Some of 
these gene products require regulated expression because they are toxic to cells, thus making large-
scale clinical production of virus challenging. These second-generation vector systems have 
improved the longevity of transgene expression by reducing cellular immune responses to the vector, 
but they have not completely solved associated immunologic problems [Engelhardt JF, et al. 1994]. 
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Third-generation adenoviral vector systems, also called gutted or helper-dependent adenoviral 
vectors (HDAd), are devoid of all viral genes and therefore able to mediate long-term, high-level 
transgene expression in the absence of chronic toxicity [Parks RJ 2000; Zhou H, et al. 2002; Palmer 
DJ and Ng P 2005].  In addition, because the HDAd genome exists episomally in transduced cells, 
the risks of germline transmission and insertional mutagenesis leading to oncogenic transformation 
are negligible [Hillgenberg M, et al. 2001]. Moreover, the deletion of the viral sequences permits a 
large cloning capacity of ~37 kb allowing for the delivery of whole-genomic loci, multiple transgenes, 
and large cis-acting elements to enhance, prolong, and regulate transgene expression [Flotte TR, et 
al. 2007]. The major hurdles for this vector system are production and generation of replication-
competent adenovirus during passaging and propagation. Several strategies using CRE/Lox [Parks 
RJ, et al. 1996] or FLP/frt [Ng P, et al. 2001] helper adenoviral vector systems have aided in 
increasing the quantity and purity of vector preparation [Palmer D and Ng P 2003]. Although helper-
dependent adenoviral vectors are devoid of all viral genes and, hence, lack cellular immunity to 
foreign viral antigens, cellular immunity for foreign transgenes remains a concern. Additionally, 
adenoviral vectors invoke a substantial humoral immune response that inhibits repeat administration 
to the lung [Yang Y, et al. 1995a]. Several strategies to reduce both humoral and cellular responses 
have been tested in animal models and include the use of immunomodulatory agents or antibodies 
[Yang Y, et al. 1995a; 1995b; 1996]. However, the death of a patient undergoing liver-directed gene 
therapy for ornithine transcarbamylase deficiency with second-generation adenoviral vectors has 
suggested that the immunology of adenovirus in humans may be poorly understood [Raper SE, et al. 
2002]. For example, a recent report has described complement activation with adenoviral particles in 
the presence of pre-existing antibodies [Cichon G, et al. 2001]. Such mechanisms may play a role in 
the acute toxicity seen in clinical trials, and further investigation into acute innate immune response 
to viral capsid proteins is needed.  
Several in vitro and in vivo studies have assessed the safety and efficacy of HDAd in pulmonary 
gene transfer, with particular interest in CF models [Fisher KJ, et al. 1996; Koehler DR, et al. 2003; 
Toietta G, et al. 2003].  Koehler et al. used HDAd-K18-CFTR bearing the human CFTR cDNA 
expressed from the K18 control elements [Koehler DR, et al. 2003]. This vector was found to express 
properly localized CFTR in cultured cells and in the apical airway epithelia of mice after intranasal 
administration (preceded by EGTA pretreatment). These results indicate that HDAd can express 
properly localized CFTR in the appropriate target cell types for CF gene therapy in vivo as well as 
suggest that this vector could benefit CF patients by reducing susceptibility to opportunistic 
pathogens. Despite some encouraging results, several outstanding challenges remained in the 
transition to larger animals models: production of the large quantities of HDAd, the need for a 
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pretreatment with a tight-juntion disruptor (e.g. EGTA), increasing procedure time and compromising 
transduction efficiency, optimization of vector delivery (intranasal administration not efficient in large 
animal models).  
 
 
Adeno-associated viral vectors 
AAVs are members of the Dependovirus genus of the Parvovirus Family. AAV consists of a very 
compact 20-nm non-enveloped icosahedral capsid surrounding a 4.7-kb single-stranded DNA 
molecule with inverted terminal repeats (ITR) of 145 nucleotides at either end. Between these ITR 
are the two viral genes, rep, which encodes functions required for replication and gene regulation, 
and cap, which encodes the capsid proteins, known as VP1, VP2, and VP3 [Berns KI 1996; Flotte 
TR and Berns KI 2005]. Members of this genus require helper virus coinfection for active replication 
in cell culture or in non-human primate experimental infections, and in the absence of a helper virus 
(such as an adenovirus or herpes virus) AAV will establish stable latency within cells without a 
significant risk of pathological effects [Berns KI, et al. 1975; Cheung AK, et al. 1980]. Primate AAV 
exists in well over 100 distinct variants, some defined as serotypes and others as genomovars, being 
AAV serotype 2 the most studied serotype. In addition to primate AAVs, a variety of other AAVs have 
been identified, including avian, canine, and bovine strains. Interestingly, many of these strains 
possess divergent tissue tropism, while seemingly retaining the basic properties of stability and non-
pathogenicity [Flotte TR, et al.  2007]. AAV derived vectors aroused as promising tool in gene 
therapy studies due to their genome simplicity, good safety profile, broad tissue tropism, long 
duration of expression, and suggestion of their superior escape from immune system surveillance 
compared with other viruses [Griesenbah U, et al. 2004]. Most recombinant AAV vectors have rep 
and cap deleted. Cells that express rep and cap and helper virus genes will package recombinant 
AAV genomes if they are flanked by ITRs and are 5 kb or less in length. Packaging is generally 
efficient with the capsid of any AAV serotype, so long as the ITRs and the rep gene are from the 
same serotype (usually both are type 2) [Hermonat PL and Muzyczka N 1984; Tratschin JD, et al. 
1985]. Progress in the development of recombinant AAV as a gene therapy vector has been 
developed to solve several long-standing hurdles in the use of this vector system: viral production 
and purification, limited packaging capacity (< 5kb). Knowledge of the molecular mechanisms by 
which AAV vector converts its single-stranded DNA genome into large concatamers has also led to 
the development of novel techniques, including cis-activation, trans-splicing and homologous 
recombination, to expand the packaging capacity of this vector system [Yan Z, et al. 2000; Sun L, et 
al. 2000; Nakai H, et al. 2000; Duan D et al. 2001; Halbert CL, et al. 2002]. The basic principle of 
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these techniques is to split the therapeutic cDNA and required promoter elements, and package 
them into two viruses, which when transfecting the same cell may recombine and generate a full-
length therapeutic gene. 
The lung was one of the first sites for in vivo transduction with first-generation AAV2 vectors. As with 
many other sites of delivery, initial transduction efficiency was relatively low, but gene transfer was 
noted to be stable and safe [Flotte TR, et al. 1992; Wagner JA, et al. 1998]. Early studies with lung 
cells in culture and in vivo also provided the initial evidence that rep-deleted recombinant AAV 
persists as a stable episome, rather than as an integrated provirus [Kearns WG, et al. 1996]. Most of 
the AAV serotypes have been tested for lung gene transfer. Although subtle differences in the 
efficiencies are found between various laboratories, the general consensus is that transduction 
efficiencies to airway epithelia follow this general order AAV-5 > AAV-6/AAV1 > AAV-2 > AAV-3 > 
AAV-4 vectors [Walters RW, et al. 2000; Duan D, et al. 2000; Auricchio A, et al. 2002; Halbert CL, et 
al. 2000]. AAV2 with capsids from serotypes 1, 5, 6 and 9 (AAV2 genome plus AAV1, 5, 6 or 9 
capsids) have been evaluated for lung gene therapy and appear to be more efficient in transducing 
airway epithelial cells than AAV2 [Sirninger J, et al. 2004; Virella-Lowell I, et al. 2005].  
Several lung-specific limitations for the use of AAV derived vectors in the pulmonary system are 
easily pointed out: (1) small packaging capacity, (2) paucity of AAV receptors in the apical surface of 
airway epithelial cells, (3) rapid turnover of airway epithelium implies limited persistence of the 
vector. The small packaging capacity of AAV precludes the use of this vector for transfer of larger 
genes as CFTR. Although there is enough space for the CFTR cDNA (over 4.4kb), it is not possible 
to include potent promoter/enhancer elements. Several strategies were and are being developed, 
including design of compact promoter elements [Haberman RP, et al.  2000], trans-splicing and 
homologous recombination [Duan D, et al. 2001; Halbert CL, et al. 2002], truncation of the 
therapeutic transgene [Ostedgaard LS, et al. 2005; Mueller C, et al. 2007]. Several primary 
attachment receptors and co-receptors have been identified for AAV: heparan sulfate proteoglycan, 
the primary attachment receptor for AAV-2, Vß5-integrin and human FGFR1, co-receptors critical for 
AAV-2 entry [Summerford C and Samulski RJ 1998; Summerford C, et al. 1999; Qing K, et al. 1999]. 
Despite the identification of these receptors and co-receptors, current studies in the field reveal that 
airway epithelial cells present few of these in their apical surface. Detailed studies in polarized 
epithelial cells have clearly indicated that apical entry of the vector is possible through an alternate 
import pathway [Duan D, et al. 2000; Sanlioglu S, et al. 2001] and treatment of airway epithelium 
with proteasome inhibitors facilitates nuclear transport of the vector. This combined vector/small 
molecule approach might be a feasible alternative to enhance AAV mediated gene transfer to the 
lung [Yan Z, et al. 2004]. Since the airway epithelium is turning over once over several months in 
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normal individuals and perhaps four times faster in CF patients, it is unclear how any episomal 
version of recombinant AAV would be able to persist for more than a few months. Studies attempting 
to improve vector persistence focus on the development of vectors capable of a greater degree of 
integration, whether it is Rep-mediated site-specific integration or some less-specific form of 
integration that might occur by blocking host pathways involved in the formation of AAV episomes 
[Flotte TR 2007]. Besides, AAV-mediated lung transduction efficiency may be improved by astute 
selection of the promoter/enhancer elements. Halbert et al. demonstrated that the use of an AAV 
vector with a hybrid promoter consisting of a CMV enhancer, a -actin promoter and splice donor, 
and a -globin splice acceptor, was most effective and lead to more than 90% transduction efficiency 
in mouse airways [Halbert SL, et al. 2007].  Liu et al. showed that rAAV was capable of transducing 
airway epithelial progenitors that had the capacity to clonally expand, both in culture and in vivo 
following lung injury. These studies suggest that recombinant AAV may be a useful vector for gene 
targeting of airway stem/progenitor cells [Liu X, et al. 2009]. 
 
 
Oncoretroviral vectors 
Retroviruses are lipid-enveloped particles comprising a homodimer of linear, positive-sense, single-
stranded RNA genomes of 7 to 11 kb. Following entry into target cells, the RNA genome is retro-
transcribed into linear doublestranded DNA and integrated into the cell chromatin. This family of 
viruses includes several varieties being exploited for gene therapy: the mammalian and avian C-type 
retroviruses (hereafter also referred to as oncoretroviruses), lentiviruses (immunodeficiency viruses) 
and spumaviruses. They tend to establish chronic infection that is usually well tolerated by the host 
but may also cause latent diseases ranging from malignancy to immunodeficiency [Coffin J, et al. 
2000]. All retroviral genomes have two long terminal repeat (LTR) sequences at their ends. LTR and 
neighboring sequences act in cis during viral gene expression, and packaging, retro-transcription 
and integration of the genome. The LTR sequences frame the tandem gag, pol and env genes 
encoding the structural proteins, nucleic-acid polymerases/integrases and surface glycoprotein, 
respectively. The viral envelope glycoprotein dictates the host range of retroviral particles through its 
interaction with receptors on target cells. Maloney murine leukemia virus (MLV)-based vectors were 
the first type of recombinant retrovirus used for gene delivery. Other examples of vectors derived 
from oncoretroviruses are Spleen Necrosis Virus, Rous Sarcoma Virus and Avian Leukosis Virus -
based vectors [Hu WS and Pathak VK 2000]. Recombinant oncoretrovirus-based genomes are 
composed of two LTR at either end of the genome, and a packing sequence (). The transgene 
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cassettes (up to 8 kb) are inserted in place of the three viral genes gag, pol and env. A useful 
property of retroviral vectors is the ability to integrate efficiently into the chromatin of target cells. 
Although integration does not guarantee stable expression of the transduced gene, it is an effective 
way to maintain the genetic information in a self-renewing tissue and in the clonal outgrowth of a 
stem cell. This is advantageous for gene transfer applications requiring sustained expression in 
proliferating targets, such as hematopoietic stem and progenitor cells. However, integration can have 
important effects on the engraftment, proliferation and survival of transduced cells because the 
integrated proviral DNA can either activate or disrupt host cell genes, resulting in immortalization 
[Calmels B, et al. 2005], clonal dominance [Fehse B and Roeder I 2007], and in worst case scenario, 
malignant transformation [Hacein-Bey-Abina S, et al. 2003; Seggewiss R, et al. 2006]. The initial 
assumption was that activation of proto-oncogenes via replication-incompetent retrovirus vectors 
was extremely unlikely when vectors integrated only once or a small number of times per target cell. 
This assumption was refuted after four of the ten patients enrolled in the severe combined 
immunodeficiency (SCID)-X1 gene therapy trial [Cavazzana-Calvo M, et al. 2000], developed clonal 
vector–containing T-cell lymphoproliferations resembling de novo acute T-cell leukemias [Hacein-
Bey-Abina S, et al. 2003]. Subsequently, several large scale surveys of murine retrovirus and 
integration profiles were carried out in cell lines, and uncovered preferences for integration within or 
near expressed genes, indicating that the risk of adjacent proto-oncogene activation might be higher 
than previously estimated based on a random integration model [Baum C, et al. 2003; Wu X, et al. 
2003; Métais J-Y and Dunbar CE 2008]. Disruption of the nuclear membrane is required for the pre-
integration complex to gain access to the chromatin, and productive transduction by retroviral vectors 
is strictly dependent on target cell mitosis shortly after entry. Since retroviral vectors can only 
transduce diving cells and because only a fraction of cells pass through mitosis at any given time, 
this severely limits the applications of retroviral vectors in gene therapy [Roe T, et al. 1993; Miller 
DG, et al. 1990; Halene S and Kohn DB 2000]. Pseudotyping consist in the substitution of one viral 
Env by another from a different virus.  Such an approach can expand the host-range of retroviral 
vectors by incorporating sequences from unrelated viruses. For example, vectors pseudotyped with 
the VSVG  can infect most cells, are particularly stable, and can be concentrated to high titers 
(excedding 1 × 1010t.u./ml ). 
The first clinical trial of human gene therapy used a MLV-based vector, to correct a genetic disorder 
known as adenosine deaminase deficiency [Blaese RM, et al. 1995.]. Also, one of the first successful 
trials of gene therapy used γ-retroviral vectors and demonstrated full correction of SCID-X1 
phenotype in 10 of 11 patients [Cavazzana-Calvo M, et al. 2000]. Unfortunatly, beginning 3 years 
after reinfusion of transduced cells, four of the ten patients developed acute T-cell leukemias, related 
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with proto-oncogene activation, has mentioned above [Hacein-Bey-Abina S, et al. 2003]. Nowadays, 
insertional mutagenesis continues to be a major concern in hematopoietic stem cell gene therapy. 
Non-conventional gene transfer vectors, as Avian Sarcoma Leukosis Viruses (ASLV), with more 
favorable integration features, are being developed and optimized [Hu J, et al. 2008]. 
The application of this vector system for in vivo gene delivery in the lung has been hindered by the 
inability of this virus to infect non-dividing cells of the airway epithelium. Nonetheless, MLV-based 
vectors have been proposed for application of in utero gene transfer, where epithelial proliferation is 
high [Duan D, et al. 1998a].  
 
 
Lentiviral vectors 
Lentiviruses have a more complex genome than other retroviridae: in addition to the gag, pol and 
env genes, they encode two regulatory genes, tat and rev, essential for expression of the genome, 
and a variable set of accessory genes. Unlike retroviruses, they rely on active transport of the pre-
integration complex through the nucleopore by the nuclear import machinery of the target cell 
[Bukrinsky MI and Haffar OK 1999]. The lentiviral strategy for nuclear targeting enables infection of 
non-dividing cells, an attractive attribute for a gene therapy vector. Also, the lentiviral integration 
profile shows a reduced propensity to hit the promoter-proximal window or regulatory motifs such as 
DNAse 1 hypersensitive sites when compared to vectors based on the gammaretrovirus MLV 
[Schröder AR, et al. 2002; Mitchell RS, et al. 2004; Derse D, et al. 2007]. Nevertheless, lentiviral 
insertion pattern with its profound preference for active genes should not represent a reliable 
safeguard against the potential risk of insertional mutagenesis [Schambach A and Baum C 2008]. 
Replication-defective vectors were originally derived from human immunodeficiency virus (HIV)-1 to 
transduce lymphocytes, but it was a VSVG pseudotyped lentiviral vector with expanded tropism 
[Naldini L, et al. 1996] that spurred applications for gene therapy. The genetic information required to 
package a functional lentiviral core in the vector was then found to be only a fraction of the parental 
genome [Vigna E and Naldini L 2000]. An important approach to alleviate biosafety concerns is the 
use of self-inactivating transfer vectors (SIN) [Zufferey R, et al. 1998; Miyoshi H, et al. 1998]. These 
vectors contain a deletion in the downstream LTR that when transduced into target cells, results in 
the transcriptional inactivation of the upstream LTR and diminishes substantially the risk of vector 
mobilization and recombination [Bukovsky AA, et al. 1999]. As the non-required genes are critical for 
viral pathogenesis, new generations of “minimal” packaging constructs have been adopted to 
increase vector biosafety: the so called third-generation lentiviral vectors. These are lentiviral SIN 
vectors containing both Rev-responsive element (RRE) and Tat cognate motif and being dependent 
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upon the co-expression of Rev in packaging cells. When using strong promoters (e.g. the promoter 
from RSV) to drive the expression of the genomic vector message in packaging cells, Tat is not 
essential to achieve efficient expression of genomic RNA [Dull T, et al. 1998]. Hybrid lentiviral 
vectors have also been derived from nonhuman lentiviruses: Simian Immunodeficiency Virus (SIV), 
Equine Infectious Anemia Virus (EIAV), Feline Immunodeficiency Virus (FIV), Caprine 
Arthritis/Encephalitis Virus and Bovine Jembrana Disease Virus, following similar approaches to 
those used for HIV-derived vectors, on the rationale that they would be more acceptable for clinical 
application because the parental viruses are not infectious to humans [Olsen JC 1998; Poeschla EM, 
et al. 1998; Mitrophanous K, et al. 1999]. However, because of the lower number and yet unclear 
role of accessory genes in non-primate lentiviruses, the actual gain in biosafety of these advanced 
design remain to be established [Vigna E and Naldini L 2000]. The obligatory RNA step in the 
retroviral lifecycle poses great constraints on the viral genome and on its exploitation for gene 
transfer purposes. The transgene expression cassette must be of limited size (8 kb), without introns 
and internal polyadenylation signals. Together with the exposure to loco-regional differences in the 
structure and activity of chromatin consequent to random integration, these factors combine to limit 
expression of the transduced genes. VSV-pseudotyped lentiviral vectors can be delivered directly in 
vivo. Lentiviral vectors efficiently transduce several non-dividing, differentiated epithelial tissues of 
rodents, humans and other species, isolated or dissociated ex vivo [Vigna E and Naldini L 2000]. 
Direct transduction in vivo appears to be more sensitive to tissue barriers limiting vector access, as 
in the case of respiratory mucosa [Johnson LG, et al. 2000] and to intracellular conditions (for 
example, cell cycle status) as in the case of hepatocytes [Park F, et al. 2000].  
The ability of lentiviral vectors to transduce a great variety of non-dividing cells, and the substantial 
flexibility in the design of the expression cassettes, remain the most important rationales for their 
clinical use. The scope of potential clinical targets includes retinal or other sensory epithelium, 
neurons, cardiac or skeletal muscle, hepatocytes, endothelial cells, dendritic cells, hematopoietic 
stem cells, and dormant tumor stem cells. The ability to transduce non-dividing cells has also 
triggered the potential clinical development of integration-defective lentiviral vectors, sometimes 
addressed as non-integrating lentiviral vectors [Yáñez-Muñoz RJ, et al. 2006; Philpott NJ and 
Thrasher AJ 2007].  The first clinical trial using lentiviral vectors was conducted to treat individuals 
suffering from the acquired immunodeficiency syndrome caused by infection with HIV-1 [Dropulic B 
and June CH 2006; Levine BL, et al. 2006]. The first clinical trial using a non-HIV based lentiviral 
vector has started December 2007. For the treatment of Parkinson’s disease, the company Oxford 
Biomedica has developed a lentiviral vector, ProSavin, based on EIAV, expressing the three key 
dopamine biosynthetic enzymes (tyrosine hydroxylase, aromatic L-amino acid decarboxylase and 
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GTP cyclohydrolase 1). In this phase I/II clinical trial the lentiviral vector was directly administered 
bilaterally into the sensorimotor putamen of late stage Parkinson’s patients.  
The development of lentiviral and pseudotyped lentiviral vectors, which can infect nondividing cells, 
has overcome some of the limitations of MLV-based vectors and has renewed interest for this class 
of retroviridae for in vivo gene delivery to the lung [Naldini L, et al. 1996]. As with other viral vectors, 
factors at the airway surface pose barriers to retroviral and lentiviral gene transfer. Airway epithelial 
gene transfer efficacy with lentiviral vector system has previously been restricted by a paucity of 
pseudotypes, which can be produced at high titres as the commonly used VSVG. However, when 
pseudotyped with VSVG, lentiviruses can only enter airway epithelial cells via the basolateral 
membrane. Therefore, apical transduction by lentivirus has been developed by using a number of 
viral envelopes from diverse origins, both in vitro and in vivo, including filovirus [Medina MF, et al. 
2003; Sinn PL, et al. 2003], baculovirus [Sinn PL, et al. 2005], influenza [McKay T, et al. 2006] and 
parainfluenza [Kobayashi M, et al. 2003] viruses. Jaagsiekte Sheep Retrovirus envelope proteins 
have been shown to stabilize pseudotyped retrovirus in the presence of lung surfactant [Coil DA, et 
al. 2001] and evaluated for  pulmonary gene transfer [Liu S-L, et al. 2004]. For example, the Ebola 
virus envelope glycoprotein has been used successfully to achieve efficient transduction of the 
murine lung epithelium and human explants [Kobinger GP, et al. 2001; Lim FY, et al. 2003] although 
generation of consistently high viral titres has been problematic. Sinn et al. [Sinn PL, et al. 2003] also 
showed that transgene expression after lung application of feline immunodeficiency virus 
pseudotyped with the baculoviral gp64 envelope applied in a viscoelastic gel formulation was 
significantly higher than observed with VSVG pseudotyped construct. Buckley et al. [Buckley SM, et 
al. 2008] performed a comparative study using HIV-based lentiviral vectors pseudotyped with the 
baculovirus gp64 envelope versus VSVG to transduce fetal, neonatal or adult airways. They 
concluded that gp64 pseudotyped lentivirus efficiently transduces airway epithelial cells after both 
fetal and neonatal administration, whereas adult administration resulted in low level transduction in 
this tissue but efficient transduction of alveoli. Intra-amniotic administration of gp64 pseudotyped 
lentivirus appeared to be the most efficient mode of airway epithelial transduction in the murine 
model. Nevertheless, Kremer et al. [Kremer KL, et al. 2007] did not see increased apical uptake of 
gp64/HIV when compared to VSVG.  
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Parainfluenza viral vectors 
Parainfluenza virus has a negative-strand RNA genome and replicate in the cytoplasm. They do not 
go through a DNA intermediate and do not enter the nucleus. This family of viruses includes several 
varieties being exploited for gene therapy: the murine parainfluenza virus type 1 or Sendai virus, the 
human Respiratory Syncytial Virus and the human Parainfluenza Virus type 3 (PIV3). All of these 
have been shown to efficiently transfect airway epithelial cells via the apical membrane using sialic 
acid and cholesterol, which are abundantly expressed on the apical surface of airway epithelial cells 
[Ferrari S, et al. 2003; Zhang L, et al. 2005]. Only Sendai virus has been assessed in animal models 
in vivo. SeV-mediated gene expression is transient (lasting for about 7 days) and currently repeated 
administration is inefficient. Several groups are assessing a variety of immuno-modulatory strategies 
to improve the use of SeV for chronic lung diseases, as CF.  
 
 
Non-viral vectors 
 
Gene delivery systems based on non-viral vectors mainly comprise cationic liposomes [Bennett CF, 
et al. 1992; Ropert C, et al. 1993; Thierry AR, et al. 1993], DNA-protein complexes [Ryser HJ and 
Shen WC 1978] and mechanic administration of naked DNA [Tascon RE, et al. 1996; Ulmer JB, et 
al. 1993]. These systems are relatively easy to manipulate, are not infectious and are not very toxic. 
Furthermore, nonviral vectors allow for the delivery of large DNA fragments and are also particularly 
suitable to deliver oligonucleotides to mammalian cells, which is an excellent feature for the 
application of antisense strategies to downregulate the expression of certain genes. A number of 
obstacles have severely limited the application of nonviral-based vectors in therapy and preclinical 
studies [Romano G, et al. 1999]. The lack of specific targeting, the low transfection efficiency and the 
fact that transgene expression is only transient make difficult the in vivo applications of nonviral gene 
delivery systems. 
 
Cationic liposomes 
Cationic lipossomes as a vehicle for delivery of DNA, have also been extensively studied in animal 
models of lung gene therapy. Major attractions of liposome mediated gene delivery include (a) an 
easily scalable gene transfer formulation for clinical trials, (b) no apparent size limitation to the DNA 
transgene being delivered, and (c) the absence of exogenous protein in the delivered complexes that 
should reduce immune responses to the vector. Despite these theoretical advantages, progress in 
developing clinically efficacious protocols has been poor owing to the inherently low efficiency of 
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gene transfer, the transient nature of transgene expression, and immunogenicity to unmethylated 
CpG dinucleotides in plasmid derived bacterial DNA [Tan Y, et al. 1999]. The mechanism of gene 
transfer with cationic liposome/DNA complexes is poorly understood, but several general features 
appear to be important in the efficacy of gene expression with these reagents including (a) the lipid 
composition, (b) the complex charge density determined by the liposome/DNA ratio, and (c) the size 
of the complex. All these factors appear to be important for efficient endocytosis and/or intracellular 
escape from endosomes, which ultimately affect the efficiency of gene transfer [Lee ER, et al. 1996; 
Felgner PL 1996]. A major obstacle in the use of liposome/DNA complex-mediated gene transfer has 
been the apparent low level of endocytosis from the apical membrane of differentiated polarized 
airway epithelia [Matsui H, et al. 1997]. Despite these limitations, studies in CFTR knockout mice 
have demonstrated the ability of CFTR-expressing liposome/DNA complexes to correct ion transport 
abnormalities [Alton EW, et al. 1993; Hyde SC, et al. 1993]. However, studies in CF human bronchial 
xenografts have demonstrated that cationic liposome can mediate complementation of mucus 
sulfation defects in CF epithelia but not ion transport abnormalities [Zhang Y, et al. 1998]. 
Improvements in cationic liposome-mediated gene delivery were made possible by a massive 
functional screen of cationic lipids for gene transfer to the lungs of mice. In this study, the Genzyme 
Corporation identified a cationic lipid called GL-67 that was 100 times more effective than previously 
evaluated common cationic liposomes [Lee ER, et al. 1996]. However, even with the most effective 
GL-67 lipid formulation, gene transfer was maximal at 2 days post-transfection and quickly 
diminished thereafter. GL-67 lipid formulation was the basis of the first lung clinical trail using 
aerosolized cationic lipids in normal volunteers [Chadwick SL, et al. 1997]. Luton and coworkers 
administrered cationic cholesterol derivatives to sheep fetuses via surgical replacement of the fetal 
airway fluid by the transfection mixture followed by tracheal occlusion. Reporter gene expression 
was detected in both trachea and lung epithelial cells and some mesenchymal cells. However, the 
level of transgene expression was relatively low and there was evidence of acute toxic effects under 
lipofection conditions [Luton D, et al. 2004].  
 
Other non-viral vectors 
Other nonviral DNA delivery systems have been described, including polymers and small synthetic 
beads. Even naked DNA diluted in hypotonic fluids can produce some gene delivery to lung 
epithelium. However, the utility of these delivery systems into the lung, particularly in vivo, has not 
yet been proven. For all of these systems, it appears that gene expression efficiency is quite low. For 
diseases such as CF, this may be a major limitation, whereas for other diseases, low-level 
expression may be adequate [West J and Rodman DM 2001]. Several groups are assessing a 
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variety of physical delivery methods, including electroporation, magnetism, ultrasound and vibration, 
in an attempt to increase the transfection efficiency of nonviral formulations. Electroporation has 
been successfully used to enhance transfection in a variety of organs including muscle [Griesenbah 
U, et al. 2004]. Some results for lung gene transfer are encouraging and demonstrate that the 
transfection efficiency of naked DNA can be enhanced in the presence of electrical fields [Dean DA, 
et al. 2003]. Clearly, important technical questions and safety considerations have to be resolved. 
 
 
Vector promoter  
 
Many gene delivery vectors use viral promoters such as the cytomegalovirus-immediate early (CMV-
IE) promoter because this promoter can drive transgene expression in many cell types. Studies 
focusing on pulmonary gene transfer have used CMV-IE for this reason because it has yet to be 
resolved which of the 40 cell types in the respiratory tract needs to be targeted for each of the 
pulmonary disorders that may benefit from genetic therapy [Davies JC, et al. 1998]. However, many 
studies of fetal gene transfer [Bestor TH 2000; Rivella S and Sadelain M 1998; Tarantal AF, et al. 
2001] have provided evidence of transgene silencing with this promoter. In addition, the development 
of pulmonary gene transfer strategies may require selective targeting of transgene expression to 
specific cells of the developing lung to ultimately be curative. Lung-specific promoters such as 
surfactant protein-C (SP-C; targets type II cells) or CC10 (targets Clara cells) are of interest for fetal 
gene transfer because SP-C mRNAs appear at early human fetal gestational ages in association 
with the epithelium where airways branch, and SP-C mRNA and proSP-C are present in distal lung 
epithelial cells before differentiation into type II cells occurs [Khoor A, et al. 1994; Wert SE, et al. 
1993]. Whitsett et al. used the gene CFTR under the direction of the SP-C and CC10 promoters in 
transgenic mice and evaluated the effects of expression in utero [Whitsett JA, et al., 1992]. The use 
of SP-C and CC10 promoters in these studies ensured CFTR expression in more differentiated cell 
types because these proteins become specific markers of their respective cell types (type II and 
Clara cell) as they differentiate. 
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Table 3 — Advantages and disadvantages of currently used vector systems for lung gene transfer 
[Kolb M, et al. 2006].  
Vector Advantage Disadvantage 
Viral   
   Retrovirus / Lentivirus Viral genes removed, no viral proteins made, 
integrates into host DNA (retrovirus) 
Possible insertional mutagenesis, cell 
division necessary (retrovirus), low titers 
   Adenovirus Efficient, transduces nondividing cells, 
produced in high titers 
Prior exposure, immune response, 
inefficient with repeated application 
   AAV Virus genes removed, no viral proteins made, 
safe, transduces nondividing cells 
Production labor-intensive, small 
packaging capacity for foreign DNA 
   Parainfluenza virus 1 
Sendai virus 
RNA genome, targets apical surface of 
epithelium, replicates in cytoplasm 
Particles are inflammatory, 
 induces immunity 
   
Non-viral   
   Naked DNA Simple, nonimmunogenic, inexpensive, safe Inefficient transduction 
   Cationic liposomes Nonimmunogenic, repeated application 
possible, safe 
Gene expression transient and low 
 
Delivery systems 
Vectors are the vehicles that carry the genetic information into the patient's cells for treatment of 
diseases. Each vector system has unique properties. Therefore, different vectors will be required for 
treating the variety of diseases amenable to gene transfer. Vectors can be introduced into cells from 
the patient's body (e.g. blood cells) and then reintroduced into the patient, or the vectors can be 
administered directly into the body through injection or even possibly by mouth. Further discussion of 
gene delivery systems: routes and time of administration, experimental models, will be restricted to 
lung directed in utero gene therapy.  
 
 
 
 
 Cell and Gene Therapy                                                     61 
 
 
In utero gene therapy 
The current approaches of gene therapy into mature organisms are confronted with several 
problems including the following: (1) the underlying genetic defect may have already caused 
irreversible pathological changes; (2) the level of sufficient protein expression to ameliorate or 
prevent the disease requires prohibitively large amounts of gene delivery vector; (3) adult tissues 
may be poorly infected by conventional vector systems dependent upon cellular proliferation for 
optimal infection, for example, oncoretrovirus vectors; (4) immune responses, either preexisting or 
developing following vector delivery, may rapidly eliminate transgenic protein expression and prevent 
future effective intervention. Early gene transfer, in the neonatal or even fetal period, may overcome 
some or all of these obstacles. [Waddington SN, et al. 2004a; 2005]. The major advantages of fetal 
and neonatal gene therapy are (1) prevention of irreversible pathological processes; (2) easier 
access to certain organs (in the case of the fetal lung, a fluid-filled structure is easier to disperse the 
gene transfer reagent) (3) reduced amount of vector required due to high ratio of vector particles to 
cells (4) ideal environment for infection of abundant stem cells and other progenitors (5) immaturity 
of immune system.  
Therapeutic gene transfer during development could be of benefit for those disorders that 
compromise prenatal structure and function and have significant morbidity soon after birth [Kawada 
T, et al. 2002; Melo LG, et al. 2004; Ryan K, et al. 2004]. Similarly, CF or 1-antitrypsin deficiency 
can result in significant morbidity and mortality [Ratjen F and Döring G 2003]. For these diseases, if 
treatment can be accomplished before severe damage occurs, then, theoretically, healthy newborns 
can be delivered free of disease at term. Lysosomal storage diseases such as the 
mucopolysaccaridoses, including Sly, Hunter and Hurler syndromes, Tay-Sachs disease and globoid 
cell leukodystrophy, demonstrate fetal pathology; nevertheless, substantial therapeutic benefits have 
been observed in mouse and dog models following neonatal gene therapy [Waddington SN, et al. 
2004b]. 
From birth to adulthood, body mass increases approximately 20-fold in humans, therefore, a 
relatively much lower amount of virus will infect a higher percentage of cells when introduced early 
rather than late in life. Also, in adult gene therapy studies of factor IX adenovirus vectors, larger 
animals (e.g. haemophiliac dogs) require far higher doses per kg body mass of viral vector to 
achieve the same levels of transgenic factor IX expression than the smaller mouse models, making it 
difficult to scale vector doses from small to large species based on body mass alone . 
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Many genetic disorders, the organ can be difficult to target after birth, for example the lung in cystic fibrosis, 
the brain in urea-cycle disorders, or the skin in epidermolysis bullosa. Fetal treatment can take advantage of 
developmental changes to access organs that are inaccessible after birth [David AL and Peebles D 
2008].  
Gene transfer to the developing fetus targets rapidly expanding stem-cell populations, providing a 
large population of transduced cells to provide a therapeutic effect. Many cell types, such as 
myoblasts, central nervous system stem cells, mesenchymal stem cells, and hematopoietic stem 
cells are more prevalent in early gestation and decrease in frequency with age. The genetic 
integration of a transgene into a pluripotential stem cell would potentially result in tremendous 
expansion of the transduced cell population with fetal and postnatal growth [Yang EY, et al. 1999a; 
1999b]. For example, after intravascular administration of lentivirus vectors to fetal mice, expression 
of a marker gene appeared to be distributed in the liver in focal clusters, suggesting they may have 
arisen from individual progenitors [Waddington SN, et al. 2003; MacKenzie TC, et al. 2002]. 
The fetus has a functionally immature immune system compared to an adult, which might be to its 
advantage. Worldwide, up to 50% of adults have pre-existing humoral immunity to adenovirus and 
adeno-associated virus serotypes from which commonly used gene therapy vectors are derived 
[Bessis N, et al. 2004] Even in the absence of a pre-existing immune sensitivity, vector 
administration to adults often results in the development of an immune response that reduces the 
duration and level of transgene expression [Gilchrist SC, et al. 2002]. Weaker fetal immune response 
towards a transgenic protein may be due to the following: (i) the reduced number of immune cells in 
early life; (ii) the developmental immaturity of cells participating in the immune response; (iii) the 
deviance of the early immune response from that of the adult, with particular bias towards a TH2 
rather than a TH1 response; and (iv) the absence of memory cells due to the naivety of the immune 
system. Immune tolerance to exogenous protein can be induced in the fetus if the protein is 
introduced before the immune system is competent. Tolerance also requires that the exogenous 
protein expression is maintained, even if at low level, and so the ability of the vector to give long-term 
expression is vital. As an example, in a mouse animal model of haemophilia B, one study showed 
that the functionally immature fetal immune system does not respond to the product of the introduced 
gene, and therefore immune tolerance can be induced [Waddington SN, et al. 2004b]. This means 
that treatment could be repeated after birth, if a single fetal treatment was not sufficient to cure the 
individual of the disease.  
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Safety and ethical issues 
Various safety issues in relation to in-utero gene therapy need to be addressed before such therapy 
can be applied clinically [Fletcher JC and Richter G 1996; U.S. National Institutes of Health. 
Recombinant DNA Advisory Committee 2000]. There is a theoretical risk that the therapeutic gene 
product or vector that is required later in life to correct a genetic disease could interfere with normal 
fetal development. This has been suggested in the case of cystic fibrosis, where in-utero infection of 
rats at 16–17 days gestation with a recombinant adenovirus carrying the human cystic fibrosis 
transmembrane receptor gene resulted in altered lung development and morphology [Morrow SL, et 
al. 1998]. The effects of a transgenic protein on developmental processes will be difficult to predict, 
depending on the time of gestation and the type of protein introduced, which will require careful long-
term monitoring. An established risk factor of integrating viral vectors is insertional mutagenesis (see 
“Oncoretroviral vectors”). The fetal system might be particularly sensitive to such events because 
integrating vectors prefer to insert their genomes into chromatin in open configuration. Whereas one 
of the aims of prenatal gene therapy is to achieve immune tolerance to the transgene and delivery 
system, vectors must be designed to be sufficiently different to the wild-type so that the immune 
system remains able to mount an effective immune response against wild-type virus infection. 
Hypothetical germ-line transmission is another potential concern, even if it was never reported, nor 
for the fetus neither for the mother. Any fetal therapy or procedure poses risks of infection, immune 
reactions and the induction of preterm labour for the fetus and the potential to harm the mother. A 
conflict of interest might potentially arise because treating the fetus might not be in the mother’s best 
interest [David AL and Peebles D 2008].  
 
Future perspectives 
Positive results of pre-clinical studies in rodent models have emerged to show proof-of-concept for a 
postnatal therapeutic effect of in utero gene delivery. Rucker et al. used an AAV serotype 1 vector 
(AAV-2/1) to deliver human α-glucosidase to the diaphragm of mice deficient in this enzyme, a 
condition which often results in death from respiratory failure in humans [Rucker M, et al. 2004]. 
Normal contractile function was restored for up to 6 months postpartum. In 2004, Dejneka et al. used 
the same AAV serotype to deliver human retinal pigment epithelium 65 to the retinal pigmented 
epithelium of Rpe65-/- mice and demonstrated restoration of visual function [Dejneka NS, et al. 
2004]. Karolewski and Wolfe also used AAV-2/1 to treat a mouse model of mucopolysaccharidosis 
type VII. This vector carrying the human β-glucuronidase cDNA was injected into the ventricle of the 
fetal brain and resulted in widespread gene expression in the brain and spinal cord and a significant 
improvement in survival after one year [Karolewski BA and Wolfe JH 2006]. Also in 2004, 
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Waddington and coworkers injected VSVG-pseudotyped HIV vector into the fetal vitelline vessels, 
which resulted in predominant expression of human Factor IX in the mouse liver (the site of 
endogenous synthesis) and achieved lifelong correction of the bleeding diathesis [Waddington SN, et 
al. 2004b]. Seppen et al achieved intraperitoneal and hepatic delivery of the transgene from direct 
intrahepatic HIV-based lentiviral vector injection. This significantly ameliorated the metabolic defect 
for one year [Seppen J, et al. 2003]. 
In the short term, two intermediate strategies for possible in utero gene therapy are emerging. The 
first involves the use of “advanced” non-integrating vectors, including helper-dependent adenovirus, 
integration-deficient lentivirus, and new adeno-associated virus serotypes [Waddington SN, et al. 
2007]. These may be applied to tissues from which the vector genome is slowly lost, such as muscle 
[Rucker M, et al. 2004], neuronal tissue in the central nervous system [Karolewski BA and Wolfe JH 
2006], and the retina [Dejneka NS, et al. 2004] for longer-term correction of genetic disease. They 
may also be applied to rapidly dividing tissues, such as the liver, to permit transient correction of 
genetic diseases which manifest perinatally until a postnatal treatment can be applied; and may also 
be applied to the fetus, placenta or extraembryonic membranes for treatment of pregnancy-
associated diseases such as pre-eclampsia [Koyama S, et al. 2006] or bronchopulmonary 
hypoplasia [Larson JE and Cohen JC 2006]. The second fetal gene therapy strategy is ex vivo 
transduction and subsequent re-implantation. This may now exploit the technological advances in 
maximizing safety and efficacy of ex vivo transduction, novel and safer integrating retroviral vectors, 
and advances in stem cell technology [Rio P, et al. 2005; Chan J, et al. 2005]. Recent advances in 
fetal medicine—particularly in imaging and minimally invasive intervention—have opened the way, in 
large animal models, for clinically relevant delivery of gene therapy vectors to virtually any fetal 
organ. However, although postnatal gene therapy has seen its first successful clinical applications, 
no trials are planned for human gene therapy in utero, now or in the near future. Indeed, many view 
the concept as having only academic value, with no potential for translation into the clinic [Coutelle C 
2008]. 
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In utero lung gene transfer 
 
The fetal lung is an attractive target organ for fetal gene transfer. There are a number of genetic and 
acquired disorders with peri- or postnatal pulmonary manifestations. These include monogenetic 
diseases like CF [Larson JE, et al. 2000] or SP-B deficiency that would presumably require long-term 
expression of the deficient or defective gene. However, there are also abnormalities of lung growth, 
such as congenital diaphragmatic hernia (CDH), or lung maturation, such as respiratory distress 
syndrome of prematurity, that could potentially benefit from strategies that achieve transient gene 
expression in specific pulmonary distributions. Additionally, an important advantage of the use of 
non-integrating viral vectors with transient gene expression is the avoidance of many of the current 
concerns regarding integrating vectors in the fetus, i.e., insertional mutagenesis, developmental 
abnormalities, and germline alteration. Success of gene therapy will depend on the choice of vector, 
defining the optimal site, route and timing of gene delivery during lung development [Yu ZY, et al. 
2007]. One additional advantage of targeting the fetal lung is that is more efficient to disperse the 
gene transfer reagent in a fluid-filled structure rather than across air-liquid interface.   
Adenoviral vectors have been used in most in utero investigations, except those using retroviral 
vectors  [Douar AM, et al. 1997; Pitt BR, et al. 1995]. Although having the advantage of being able to 
be concentrated in high titers and providing efficient gene transfer, adenoviral vectors may lead to 
substantial inflammation and even fetal loss [Iwamoto HS, et al. 1999; Yang EY, et al. 1999a]. 
Retroviral vector use in in utero applications has been limited because retroviral infectivity is reduced 
by amniotic fluid [Douar AM, et al. 1996]. Previous work, however, suggests that AAV gene transfer 
to respiratory epithelia is limited by vector entry and postentry interactions of cellular components 
with vector DNA [Duan D, et al. 1998b]. In particular, well-differentiated pulmonary epithelial cells 
may lack the factors necessary for efficient AAV-mediated gene expression. AAV-mediated gene 
expression is much more efficient in undifferentiated pulmonary cells [Bals R, et al. 1999]. These 
observations suggest that one strategy for generating higher degrees of vector entry and gene 
expression in AAV may be targeting rapidly dividing undifferentiated epithelial cells with an in utero 
or neonatal approach. The neonatal approach has been studied [Rubenstein RC, et al 1997; Zeitlin 
PL, et al. 1995] but studies of in utero administration of AAV are limited to recent investigations of the 
effect of intraperitoneal and intramuscular delivery in a mouse model [Lipshutz GS, et al. 2001; 
Mitchell M, et al. 2000]. Pulmonary applications of in utero lentiviral gene transfer in vivo have 
broadened. Following successful demonstration of in vivo gene transfer to human xenografts 
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[Goldman MJ, et al. 1997] and rabbit airways [Wang G, et al. 1999] groups have demonstrated 
efficacy of in utero vector delivery. Following intrapulmonary delivery of an HIV vector encoding 
green fluorescent protein (GFP) into rhesus monkey fetuses, Tarantal et al. [Tarantal AF, et al. 2001; 
2005] reported gene expression in pulmonary epithelia confirmed by direct fluorescence and Q-PCR. 
Lim et al. [Lim FY, et al. 2003] had similar success in targeting epithelia in human fetal tracheal 
xenografts using HIV-LacZ. Transgene expression remained detectable 9 months posttransduction. 
 
Route of administration 
If fetal gene therapy is to be clinically applicable, developments in vector technology must be 
accompanied by improvements in minimally invasive methods of delivering vectors to the fetus. 
Traditionally, invasive surgical techniques such as maternal laparotomy or hysterotomy have been 
performed to access the fetus in small- and even large-animal models. However, in clinical practice, 
minimally invasive techniques such as ultrasound-guided injection, or even fetoscopy, could be used 
to deliver gene therapy to the fetus with less morbidity and mortality.  
Experiments that use intra-amniotic injection of oligodeoxynucleotides have demonstrated excellent 
expression in fetal skin, but no expression in the fetal lung [Hayashi SI, et al. 1996]. Intra-amniotic 
administration of adenovirus showed low level pulmonary expression of transferred marker genes in 
3 of 4 studies [Sekhon HS and Larson JE 1995; McCray PB Jr, et al. 1995; Douar AM, et al. 1997; 
Holzinger A, et al. 1995]. In contrast, much higher levels of gene transfer were observed in the 
proximal gastrointestinal tract (oropharynx and esophagus) because of fetal swallowing of amniotic 
fluid. Thus, the net efflux of fetal hmg fluid probably predominates over any influx of fluid with fetal 
breathing movements, preventing vector access to the lung. An alternate approach is direct 
administration of vector into the fetal trachea. This has been performed by open fetal surgical 
[McCray PB Jr, et al 1995; Vincent MC, et al 1995] or fetoscopic techniques [Sylvester KG, et al. 
1997].  
Intra-tracheal injection of retroviruses, which are much less efficient at transduction than adenovirus, 
resulted in only spotty single-cell areas of gene transfer [Pitt BR, et al. 1995]. Results with 
recombinant adenovirus have been much more successful. Several studies have documented high 
efficiency marker gene transfer in the lung parenchyma of late gestation sheep within 7 days after 
intratracheal injection of first generation recombinant adenovirus [McCray PB Jr, et al 1995; Vincent 
MC, et al 1995; Sylvester KG, et al. 1997]. Although only 1 study quantified transduction of distal 
alveolar cells as high as 12% [McCray PB Jr, et al 1995], areas of higher level transduction were 
observed in other studies. A notable finding was that the distal lung parenchyma appeared to be the 
major site of gene transfer. In 2 of 3 studies, no expression could be detected in any large airways 
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[Vincent MC, et al 1995; Sylvester KG, et al. 1997]. Tracheal gene transfer was only observed in I 
study and may have been due to concomitant epithelial injury due to instrumentation or vehicle 
toxicity [McCray PB Jr, et al 1995]. One interpretation is that the late gestation fetal airways are well 
differentiated and similar to adult airways in terms of tight junctions and basolateral distribution of 
viral receptors. This conclusion is substantiated by electron microscopy studies [Schneeberger EE, 
et al. 1978]. Although discouraging for the purposes of treating CF, an encouraging finding was that 
parenchymal gene transfer was specifically localized to type II alveolar epithelial cells by 
colocalization with sheep SP-B protein [Sylvester KG, et al. 1997]. Thus, recombinant adenovirus 
can target the appropriate cell type for treating SPB deficiency. Despite the initially high gene 
transfer efficiency with recombinant adenovirus, long-term results have been disappointing. The 
appearance of cellular inflammation at about 7 to 10 days heralds loss of transferred gene 
expression [McCray PB Jr, et al. 1995; Yang EY, et al. 1999c]. This suggests that the late gestation 
fetus reacts in a manner very similar to adult animals in response to first generation adenoviruses. 
With the use of completely deleted recombinant adenoviruses, which are devoid of adenoviral 
structural genes, and with application of fetal gene therapy earlier in gestation, it is conceivable that 
transferred gene expression can be prolonged. In summary, initial results with first generation 
adenoviruses in the fetal lung have been promising. Clearly, administration of vector can be 
achieved via minimally invasive, fetoscopic methods. Distribution of vector is broad throughout the 
lung, and gene transfer occurs in a high percentage of cells. The limited pattern of gene expression 
in parenchymal tissues would be favorable for the purposes of treating SP-B deficiency, yet because 
conducting airways generally did not show transferred gene expression, recombinant adenovirus 
may not be the optimal vector for treating CF. With further improvements in reducing the 
immunogenicity of recombinant adenovirus and further analysis of the optimal timing of vector 
delivery during gestation, prolonged gene expression may be obtainable [Yang EY, et al. 1999b].  
 
 
Time of administration 
Accessing the respiratory epithelium prior to acquisition of a fully differentiated phenotype, that has 
proven resistant to virus-mediated transduction, and the possibility of successfully targeting epithelial 
progenitor cells with integrating vector systems such that durable therapeutic benefit results 
[Waddington SN, et al. 2004a]. Gene delivery via the airway lumen becomes theoretically possible 
from the beginning of the pseudoglandular stage of fetal lung development, occurring between 5 and 
17 weeks of gestation in humans (term 40 weeks), but is more realistically achievable during the 
subsequent canalicular phase, which extends through to week 26 of gestation [Jeffrey PK 1998]. 
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During the pseudoglandular stage airway branching is completed and epithelial differentiation and 
maturation begins in the proximal airway and progresses distally, with the upper lung lobes 
developing slightly ahead of the lower lobes. In the monkey the pseudoglandular stage occurs 
between 55 and 110 days (term 165 days) and the canalicular stage between 110 and 138 days 
gestation; in the fetal lamb, where lung development has been well characterised and shown to 
parallel that of the human fetus, the pseudoglandular stage of lung development occurs between 40 
and 80 days of gestation (term 147 days) [Alcorn DG, et al. 1981].  
 
 
Experimental models 
Fetal gene transfer studies on rodents take advantage of the wide range of disease models, short 
gestation time and the need for relatively small amounts of vector. However, it is important to 
translate these studies to larger animal models if the goal of human fetal gene therapy is to be 
achieved. Larger animal models are valuable since they are more relevant to humans in terms of 
gestation time, maturation of the fetal immune system, and fetal mass as well as in relation to the 
vector application technology. The importance of a nonhuman primate model for these studies is 
related to the similarity of rhesus monkeys to humans developmentally and anatomically. For 
example, the fetal monkey lung passes through the same stages of development at similar 
gestational time points compared to the human fetus, and during prenatal and postnatal life, the 
human and nonhuman primate lung are still developing [Fannuchi MV and Plopper CG 1997]. In 
addition, human and nonhuman primates share a variety of pulmonary cell phenotypes not found in 
other species, and the overall structure of the monkey lung is more similar to that in the human than 
any other mammalian species [Plopper CG and Hyde DM 1992]. It is likely that non-human primates 
will be the ultimate animal model that will be used for safety studies in the immediate preparation for 
a clinical trial of fetal gene therapy. However, the high maintenance costs and breeding conditions 
prohibit their use in the routine development of novel injection techniques. Sheep are much easier to 
breed and maintain and are a well established animal model of human fetal physiology. 
 Cell and Gene Therapy                                                     69 
 
 
 
Table 4 - In utero lung gene transfer studies’ synopsis. 
Route 
Type 
vector 
Development 
stage 
Targeted  
compartment 
References and 
experimental model 
Intrapulmonary 
(US) Lentiv  
Embryonic Airway epitehlium Tarantal 2001  (Rhesus monkey) 
Pseudogland 
and early 
Canalic 
Airway epithelium (type I and II 
cells), endothelium, macrophages 
Tarantal 2001 and 2005 
(Rhesus monkey) 
Intratracheal 
Adv Canalic to Saccular 
Trachea and bronchial epithelium 
(including type II cells) 
David 2003, 2006, Peebles 
2004 (Transduction 
enhancers), Sylvester 1997 
(TO); sheep. 
Lentiv Saccular Bronchiolar airway Yu 2007  (HIV; sheep) 
Oncoretro Saccular Airway and respiratory epithelium; submucosal space   
Pitt 1995 
 (MLV; sheep) 
Cationic 
lipossome Canalic 
Trachea and bronchial epithelium; 
few mesenchymal cells Luton 2004 (sheep; TO) 
Intraamniotic 
Adv 
Embryonic No significant expression  Douar 1997 (mouse),  Buckley 2005 (mouse) 
 
Pseudogland 
Low levels of expression  McCray 1995 (mouse) 
Trachea and bronchioles epithelium  Buckley 2005 (mouse) 
Airway epithelium (except trachea 
and alveoli)  
Douar 1997 (mouse), Sekhon 
and Larson 1995 (rat), Cohen 
1998 (mouse) Morrow 1998 
(rat; CFTR); Cohen and Larson 
2005, 2006 (rat; 
CFTR/ASCFTR; NI-CDH, 
TIUKO) 
Some cells in the parenchyma 
surrounding small airways  
Cohen 2008  
(mouse; CFTR) 
 
Canalic 
Trachea, epithelial cells (including 
type I and II cells), airway 
Cohen 2008 (mouse; CFTR) 
Larson 2000 (Rhesus monkey; 
CFTR) 
Saccular 
Trachea, airway epithelium (small 
bronchus and bronchiolus) and 
alveoli 
Holzinger 1995 (sheep), 
McCray 1995 (sheep; CFTR; 
TO) 
AAV 
Canalic Pulmonary epithelium including type I and II cells 
Garrett 2003 (mouse, rat and 
Rhesus monkey) 
Saccular Trachea, pulmonary epithelium including type II cells Boyle 2001 (rabbit) 
Lentiv Pseudogland Airway epithelium  Buckley 2008 (HIV; mouse) 
Intravenous 
(yolk sac 
vessels) 
Adv 
Embryonic 
Pseudogland 
Saccular 
Epithelium; Endothelium Schachtner 1999 (mouse) 
AAV Pseudogland (Lung) Bilbao 2005 (mouse) 
Lentiv Pseudogland Interstitial cells Waddington 2003  (EIAV; mouse) 
Intraperitoneal 
AAV Pseudogland Airway Lipshutz 2001, Bilbao 2005 (mouse) 
Oncoretro Canalic to 
Saccular 
Epithelium, fibroblasts, 
macrophages of alveoli, SMC 
Porada 2005 
(MSLV; sheep) 
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AAV- adeno-associated viral vector; Adv- Adenoviral vector; ASCFTR- Antisense CFTR; Canalic- canalicular stage of 
lung development; CFTR- cystic fibrosis transmembrane receptor; EIAV- equine infectious anemia virus; HIV- human 
immunodeficiency virus; Lentiv- Lentiviral vector; MLV- murine leukemia virus; NI-CDH- Nitrofen-induced Congenital 
Diaphragmatic Hernia; Oncoretro- oncoretroviral vector; Pseudogland- pseudoglandular stage of lung development; 
SMC- smooth muscle cells; TIUKO- transient in utero knockout;  TO- tracheal occlusion; US- ultrasound guided. 
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Aims  
Unique therapeutic opportunities occur during fetal life, related with normal developmental events, 
which favor prenatal over postnatal treatment. These opportunities create a compelling rationale for 
the prenatal treatment of pulmonary fetal, pediatric and even adult disorders, with potentially less 
morbidity and mortality than that associated with currently available portnatal treatments. The 
combination of advances in maternal screening for fetal diseases, fetal imaging, molecular diagnosis 
and gene chip technology shift the diagnosis window, of most anatomic and genetic diseases, for 
early gestation. Fetal treatment offers many advantages: developmental plasticity allow restoration of 
function after genetic correction; immature immune system allow the development of tolerance to the 
vector and transgenic protein; higher frequency and more accessible populations of stem cells and 
progenitor cells; high vector/cell ratio reduces the amount of vector to be administred.  
There are a number of genetic and acquired disorders with peri or postnatal pulmonary 
manifestations. These include monogenetic diseases like cystic fibrosis or surfactant protein B 
deficiency, congenital diaphragmatic hernia, congenital cystic adenomatoid malformation, respiratory 
distress syndrome of prematurity that could potentially benefit from prenatal strategies. Rather than 
consider gene replacement therapy to monogenetic diseases, we intented to modulate lung growth 
and maturation, envisaging therapeutic applications in diseases like CDH or respiratory distress 
syndrome of prematurity. Congenital diaphragmatic hernia (CDH) is a malformation that remains with 
high mortality mainly due to fetal lung hypoplasia and pulmonary hypertension, despite sophisticated 
postnatal clinical approach. Now, it’s possible to stratify the fetuses into low- and high-risk groups 
and offer antenatal therapy for the later ones, in order to promote prenatal lung growth and/or 
modulate pulmonary hypertension.  
The developing lung has been considered an attractive target organ for fetal gene transfer, however 
to achieve our purposes we needed to develop a new method that selectively target the fetal lung 
early in gestation. Several issues should be addressed: route of administration, type of vector, safety 
and vector biodistribution, gene transfer efficiency and kinetics (transient or sustained), cellular 
target. Following the establishment of a new model of intrapulmonary in utero gene transfer, it was 
our intent to modulate lung development acting upon key players envisaging a potential induction of 
growth in hypoplastic lungs and/or maturation in abnormally immature lungs. 
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Thus, the specific aims of this study are: 
 
1. To develop a new approach to fetal lung gene therapy 
  1.1. To selective target rat fetal lung using ultrasound guided microinjections 
  1.2. To compare different viral vectors for fetal lung gene therapy 
 
2. To study the effects of FGF10 gene transfer in modulation of fetal lung growth 
  2.1. To induce over-expression of FGF10 by adenoviral gene transfer 
  2.2. To characterize the effects of FGF-10 on fetal lung growth 
  2.3 To clarify the regulatory mechanisms by which FGF-10 acts on fetal lung growth  
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Discussion 
 
Advances in prenatal diagnosis of genetic and congenital disorders with progressively more sensitive 
techniques may increase opportunities for consideration of prenatal gene therapy. There are a 
number of genetic and acquired disorders with peri or postnatal pulmonary manifestations. These 
include monogenetic diseases like cystic fibrosis or surfactant protein B deficiency that would 
presumably require long-term expression of the deficient or defective gene. However, there are also 
abnormalities of lung growth, such as congenital diaphragmatic hernia, or lung maturation, such as 
respiratory distress syndrome of prematurity, that could potentially benefit from strategies that 
achieve transient gene expression in specific pulmonary distributions. Considered an attractive target 
organ for fetal gene transfer, the developing lung, poses also some obstacles that would only be 
overcome with the development of a variety of gene transfer methodologies: different types of vector, 
optimal site, route and timing of gene delivery.  
The goal of this thesis was to develop new strategies to specifically target the developing lung in 
early stages of development. The optimized model would constitute an important tool of in utero 
gene delivery. After this, the newly established gene transfer model was used to modulate lung 
growth and development, by inducing transient overexpression of a key factor in lung development, 
FGF10, in the fetal rat lung. This study, not only contributed for further characterization of FGF10 
role in normal lung development, but also provided an unique insight into developmental 
mechanisms that may contribute to congenital cystic adenomatoid malformation (CCAM) etiology.  
In chapter 2, we report the feasibility of using ultrasound biomicroscopy (UBM) to perform in utero 
intrapulmonary injections in rats at the pseudoglandular stage of lung development. Several routes of 
vector administration have been utilized to achieve prenatal gene transfer to the lung including intra-
pulmonary. Intra-amniotic and systemic approaches share the same limitations of being nonspecific 
for fetal lung. Intratracheal and intrapulmonary delivery, although more specific to the lung, have 
previously only been performed in large animal models, such as ovine and non-human primates [Pitt 
BR, et al., 1995; Sylvester KG, et al 1997; David AL, et al. 2003, 2006; Luton D, et al. 2004; Peebles 
D, et al., 2004; Yu ZY, et al. 2007; Tarantal AF, et al. 2001, 2005]. One of the major concerns in 
gene transfer protocols is to target a specific organ/system, in our case, we aimed to specifically 
target the lung. This was only possible, by using a relatively new imaging technology: the ultrasound-
guided biomicroscopy (UBM).  UBM utilizes high-frequency (20–100 MHz), pulse-echo ultrasound for 
imaging live tissues and organs, allowing near microscopic resolution and has been previously 
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utilized for fetal brain injections [Turnbull DH, et al. 1995; Foster FS, et al. 2000]. Using UBM, we 
could successfully target the rat lung at E15.5, which corresponds to the mid-point of the 
pseudoglandular stage of lung development. In fact, we attempt to target the developing lung earlier, 
at E13.5 and E14.5, however the lung bud was very difficult to visualize and mortality was 
unacceptably high. Biodistribution of the viral vectors was evaluated and we concluded that gene 
delivery was localized to the injected lung with the only exceptions being the needle track through 
the thorax and a very low copy number in the heart. This could be due to inadvertent injection of the 
heart but is more likely due to the small amount of intravascular injection associated with this 
technique. A few animals had EGFP expression noted by stereoscopic fluorescent analysis in the 
skin or eye. However, in the animals selected for PCR analysis, these tissues did not have 
statistically higher gene copy numbers than PBS controls. This discrepancy likely represents 
inconsistent amounts of leakage of the vector into the amniotic space during removal of the 
micropipette. The lack of pulmonary epithelial transduction in these animals despite intra-amniotic 
leakage is most likely explained by the very minimal volume of leakage into the amniotic space 
relative to the volume of injectate in the intra-amniotic injection experiments as well as the timing of 
the injection.  
The timing of vector administration was definitively one of the major challenges of this work. We 
aimed to establish a model of lung in utero gene transfer, envisaging the manipulation of normal and 
abnormal lung development during pseudoglandular stage. This stage, characterized by intense 
branching morphogenesis, is the period of greatest overall growth of the airways and vasculature of 
the fetal lung, and corresponds to a stage of immunologic immaturity. Therefore, gene transfer 
during this period has the potential to have major effects on the key elements of lung growth with 
minimal potential for detrimental immune responses. Also, stem-cell targeted gene transfer and 
intervention in rodent models for human diseases (e.g. nitrofen-induced congenital diaphragmatic 
hernia rat model and cystic fibrosis murine models), that requires pertinent therapeutic window 
periods, would benefit from gene delivery early in lung development.  
Regarding the type of vectors we used first-generation adenoviral and EIAV-based lentiviral vectors. 
We chose to study first-generation adenoviral vectors rather than adeno-associated viral vectors 
because we wished to see rapid, high-level expression of the marker gene. EIAV-based owing to the 
fact that HIV-1-based lentiviral vectors have not shown high efficiency transduction [Hofmann W, et 
al. 1999, Romano G, et al. 2000] in many tissues and owing to the successful application of EAIV 
vectors in fetal rodent models by Waddington et al. [Waddington SN, et al. 2003]. Adenovirus has 
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been one of the most extensively studied recombinant viral systems because of its high transduction 
efficiency, rapid expression, accommodation of large transgene inserts, and high titers [Romano G, 
et al. 2000; Senoo M, et al. 2000; Breyer B, et al. 2001; Driskell RA and Engelhardt JF 2003]. The 
primary problem with adenovirus is its high immunogenicity and propensity to invoke strong immune 
responses. Previous studies documented this problem with intratracheal administration in late 
gestational fetal lambs; however, in the same model, no significant inflammation is observed with 
adenoviral administration during the preimmune phase of lamb immunologic development [Yang EY, 
et al. 1999b]. Similarly, as we would predict from the stage of rat immune development at E15.5, we 
saw no overt inflammatory response. In contrast to adenovirus, lentiviral vectors are relatively non-
toxic and minimally immunogenic and can stably integrate transgene into dividing and non-dividing 
cells with subsequent long-term gene expression [Naldini L, et al. 1996, Zufferey R, et al. 1997]. The 
main disadvantages are the low titers that are usually obtained in vitro [Romano G, et al. 2000]. EIAV 
vector obtained titers were relatively low (107–108 infectious particles per mL), therefore we needed 
to inject the maximal tolerated volume of 350 nL of EIAV to achieve significant transduction. The 
rapid loss of EGFP expression in the adenoviral-transduced lungs was expected due to the episomal 
location of adenoviral gene expression, the small volume of vector administered, and the rapid 
proliferation of fetal lung tissue. We confirmed that EIAV to stably integrate transgene into the host 
genome. As expected, adenoviral vector expression appeared quickly and was transient, whereas 
lentiviral vector expression was relatively delayed and persisted through the time period of this study. 
Adenoviral would be the most appropriate vector to use when the goal is to induce rapid and 
transient overexpression of a gene in this model, whereas, lentivirus would be a more suitable vector 
to induce sustained and long-term gene expression.  
Interestingly, both viral vectors efficiently transduced the interstitial compartment of developing lung, 
Unexpectedly, in contrast to intra-amniotic injections, both vectors selectively transduced interstitial 
cells and not alveolar or airway epithelial cells, or vascular endothelial cells. There was no 
expression of reporter gene in the surface epithelium of airways or in the vascular endothelium. We 
were not able to definitively identify the cells in this study owing to a lack of specific markers for cell 
types in the interstitium. Although we suspected that the cells were mesenchymal in origin, they do 
not stain with vimentin, a common mesenchymal and fibroblast marker. Attempts to colocalize EGFP 
staining with SP-B, a surfactant protein expressed in type II pneumocytes, confirmed that the 
transduced cells were not epithelial, and that they were located within the interstitial compartment of 
the lung. This is in distinct contrast to the epithelial restricted expression seen with intra-amniotic 
vector injections. Although the obvious explanation is the route of injection, in the two previous 
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studies of direct lung transduction in primates using human immunodeficiency virus-1 lentiviral 
vectors, only epithelial expression was described, so this appears to be a model-dependent 
observation. At the time of publication, this was the first observation of this pattern of parenchymal 
expression with any reports of prenatal lung gene transfer. Recently, Cohen and coworkers [Cohen 
JC, et al. 2008] were able to induce the expression of reporter gene in parenchymal cells 
surrounding small airways, following intraamniotic administration of adenoviral vector in mouse 
fetuses at E16. The adenoviral vectors contained full-length CFTR, a short anti-sense CFTR gene 
fragment, or a reporter gene as control were used in an intraamniotic gene therapy procedure to 
transiently modify CFTR expression in the fetal lung. The modulation of gene expression of lung 
parenchymal cells is, in this case, related with the use of BAT-gal transgenic reporter mouse line, 
expressing β-galactosidase under a canonical Wnt/β-catenin-responsive promoter. The observation 
of transduction of distinct cell populations within the lung with different routes of transduction raises 
the possibility of manipulating gene expression in specific and separate cell populations within the 
developing lung. This may have interesting applications toward understanding mesenchymal 
epithelial inductive interactions during the pseudoglandular phase of lung development.  
The ability to achieve gene transfer by direct intrapulmonary injection in a rat model provides a novel 
tool for the exploration of potential therapeutic strategies for lung disorders and for biological studies 
examining the effects of specific genes on lung development. Obvious advantages of this technique 
include ease of manipulation, minimal expense, and, if translatable to the mouse, the availability of 
well-characterized murine models of human lung diseases [Boyd RL, et al. 1984; Muller RM, et al. 
1985; Tenbrinck R, et al. 1990].  
 
 
The established model of intrapulmonary in utero gene transfer would constitute an important tool in 
pursuing the studies of the mechanisms related to lung development in normal and hypoplastic 
lungs. We aimed to modulate lung development acting upon key players envisaging a potential 
induction of growth in hypoplastic lungs and/or maturation in abnormally immature lungs.  
After long time, our lab has focused our research on the pathophysiology and development of 
potential prenatal therapeutics for CDH. The possibility to revert fetal lung hypoplasia, one of the 
major causes of mortality in CDH infants, by prenatal gene transfer, was appealing. Bearing that in 
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mind, we considered that rapid, high-level of expression of the transgene was preferable whether 
sustained long-term expression was not required. Therefore, we pursue our studies with modulation 
of lung development by intrapulmonary adenovirus-mediated gene transfer, as described in chapter 
3. 
After an extensive review of the main factors involved in the branching process and those implicated 
in CDH, we selected two strong candidates for transgene: FGF10 and TTF1. FGF10 null mice lack of 
lung development and die after birth [Sekine K, et al. 1999] and TTF-1 null mice have disruption in 
lung branching morphogenesis and also present a perinatal lethal phenotype [Kimura, et al. 1996]. In 
addition, both factors are reduced in experimental CDH [Chinoy MR, et al. 2001; Teramoto H, et al. 
2003]. Also, Acosta and collaborators, using lung explants from animals exposed to nitrofen, 
demonstrated that this toxic induced an almost complete arrest of lung budding in the left lung and 
significantly decreased branching in the right lung [Acosta JM, et al. 2001]. Exogenous FGF-10 
produced a significant lung growth by stimulating lung branching morphogenesis in both control and 
nitrofen exposed lungs in culture. Gains in branching with FGF-10 after nitrofen exposure were very 
impressive with the right lung restored to the same number of branches as the wild-type lungs grown 
without the benefit of FGF-10, whereas the number of branches in the left lung increased by 77% 
[Acosta JM, et al. 2001]. Besides these evidences about the potent role that FGF10 has in lung 
growth another theoretical advantage of FGF10 as compared to TTF-1 is that the former can induce 
directly cellular growth, whereas the latter need to bind to a promoter region and activate its target 
gene. Therefore, we decided to construct an adenoviral vector with FGF10 as the transgene and to 
analyze the effects of FGF10 transient overexpression by fetal lung gene transfer during the 
pseudoglandular stage. 
FGF10 overexpression from the mesenchyme was focally and transiently induced at different 
locations and developmental stages in the fetal rat lung using our method of intraparenchymal gene 
transfer. In the area of forced FGF10 expression, pulmonary morphogenesis was markedly 
perturbed with the very rapid appearance of localized cystic lung malformations. The type of 
malformation observed was developmental stage and location dependent, with the spectrum ranging 
from macrocystic malformations lined by predominantly bronchial epithelium, to focal microcystic 
malformations lined by predominantly alveolar epithelium. The malformations were detectable by 
prenatal ultrasound examination within 24 hours after vector injection, and persisted until at least 1 
week after birth. Whether examined grossly, by pre or postnatal imaging, or microscopically, the 
malformations appeared remarkably similar to the spectrum of human malformations characterized 
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as CCAM. Preliminary in vitro results, confirm that microinjection of adenoviral vector encoding 
rFGF10 induces focal cystic formations in fetal rat lung explant cultures (data not shown).    
As expected, overexpression of FGF10 in this study was focal rather than diffuse, and was 
expressed in interstitial cells rather than ectopically from respiratory epithelium. The expression 
profile of FGF10 demonstrated that there is a peak approximately 24 hours after injection with rapid 
decrease of transgene expression. Preliminary results of in vitro study showed that fetal rat lung 
explants injected with Ad-rFGF10 exhibited an increase of phosphorylated ERK1/2, whereas no 
differences were observed in p38, Akt and Src phosphorylation, when compared with PBS injected 
explants. These data confirm the involvement of ERK-MAPK pathway in the formation of FGF10-
induced cyst malformation.  
Current models in branching morphogenesis propose that FGF10 and reciprocal influences such as 
Bmp4 and Spry2 regulate lung development. Highly localized expression of fgf10 in the 
mesenchyme adjacent to the tip of the nascent airway stimulates proliferation and growth outward. 
FGF10 signaling induces a steady increase in Bmp4, Spry2 or other reciprocal factors in epithelial 
cells. Bmp4 and Spry2 are inhibitory to epithelial cell proliferation/movement arresting the outward 
movement of the developing airway [Mailleux AA, et al. 2001; Weaver M, et al. 2000]. The distinct 
phenotypes for cystic formations, secondary to early versus late overexpression of FGF10, can be 
interpreted. During early stages of branching morphogenesis, high levels of mesenchymal FGF10 
expression would be expected to induce a burst of proliferation and outward migration of the 
epithelium responsive to FGF10, with less proliferation at branch points where Bmp4 and other 
antagonists are expressed. Our results showed that BMP4 and for Spry2 inhibitory effect over 
FGF10 might not be effective in lungs. Thus, at the early time point, within the first 24 to 48 hours 
when FGF10 levels are high unopposed action of FGF10 allows the rapid formation of large cysts. In 
contrast, in late injected lungs, expression of these two factors increase in the epithelium 
surrounding cystic areas, leading to the formation of smaller cysts. Taking in consideration the 
spatial variable of our model: proximal versus distal injections, we suggest that, during 
pseudoglandular stage, lungs injected in the proximal airways, where fewer branch points exist, and 
high columnar epithelium predominates, unopposed FGF10 signaling would be predicted to result in 
large cysts lined by predominantly bronchial epithelium. Whereas, in distal airways, where multiple 
branch points are already present and cuboidal epithelium predominates, smaller and more 
numerous cysts would form lined by predominantly alveolar epithelium. During the canalicular stage 
of lung development only terminal branching occurs, so FGF10 overexpression might stimulate short 
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segments of responsive epithelium into small cyst and differentiated adenomas formation. Curiously, 
the binome Hoxb-FGF10 is a well established as the promoter of cystic like structure formation in the 
chick lung. Studies showed that the pattern difference between the branched airway (dorsal) and the 
air-sac (ventral cystic structure) in chick lung is due to the difference in the diffusion coefficient of 
FGF10 between these two regions [Miura T, et al. 2009], and that that the cyst-branch difference in 
this system is caused by region-specific mesenchymal properties related to Hoxb cluster nested 
gene expression [Sakiyama J, et al. 2000]. In our study, we observed rapid formation and 
persistence of the cystic lesions. These findings support the hypothesis that FGF10 is involved in the 
early inductive events in CCAM formation and that continued presence of FGF10 is not necessarily 
required in the natural evolution of CCAM malformations.  
CCAMs are relatively rare developmental abnormalities of the lung that cause significant morbidity 
and mortality in infants due to associated respiratory distress, lung hypoplasia, fetal hydrops and 
pulmonary infections. The lesions are currently described as hamartomatous lesions, i.e. normal lung 
tissues in a disorganized spatial arrangement. In these lesions, the terminal bronchioles develop a 
nonsystematic overgrowth, with a consequent suppression of alveolar growth. The result of this 
process is a multicystic mass that replaces the normal lung structure. Human CCAMs are confined to 
a single lobe and can be classified as macrocystic or microcystic [Wilson RD, et al. 2006; Laje P and 
Liechty KW 2008]. 
Interestingly, the ultrasound and MRI appearance, lobar distribution, and ultrasound classification of 
the malformations observed were strikingly similar to human CCAM. FGF10 gene transfer during the 
pseudoglandular stage resulted in macrocystic lesions by ultrasound classification that were 
confirmed by MRI evaluation at Postnatal Day 7. A completely different ultrasound pattern was 
observed when gene transfer was performed during the canalicular stage—no cysts were visualized, 
but well-defined areas of increased echogenicity could be identified. Other classification of CCAM, 
based on clinical features, macroscopic and microscopic criteria, proposed by Stocker [Stocker JT 
1994], classified CCAM into five 5 types. Depending on differences in cytodifferentiation, these five 
categories could be assembled into two major subtypes: CCAM types 1, 2, and 3, with a bronchiolar-
type epithelial differentiation; and a second subtype consisting of CCAM type 4, which has an acinar-
alveolar epithelial differentiation. Despite CCAM pathogenesis remains unknown, several authors 
have hypothesized that to originate at distinct stages of lung development the first subtype (CCAM 
types 1, 2, and 3) may develop at the pseudoglandular stage, and the second subtype (CCAM type 
4) may be due to a late event that disrupts branching of the distal acinar structures in the saccular 
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period [Morotti RA, et al. 1999]. Our results support this pathophysiologic hypothesis: 
pseudoglandular stage injections induced cysts resembling bronchiolar-type epithelial differentiation, 
whereas canalicular stage injections induced cysts resembling acinar epithelial-type differentiation of 
human CCAMs.  
Several studies, using human fetal resected CCAM tissue, tried to discern factors that could be 
responsible for this pathology. Volpe et al. demonstrated that Hoxb5, in human fetal resected CCAM 
tissue, was maintained in a higher level of expression, characteristic of early stages of lung 
development [Volpe MV, et al. 2003]. Recently, these authors have also demonstrated that specific 
cell adhesion molecules, such as -2 integrin and E-cadherin, important to lung development and 
airway morphogenesis are altered. They also suggested that CCAM pathogenesis might be 
associated with potentially altered integrin cytoplasmic signaling [Volpe MV, et al. 2009]. Fgf 7 gene 
expression or protein production was evaluated and no differences were found when compared with 
normal lungs [Cass DL, et al. 1998]. PDGF-BB gene expression and protein production were found 
to be increased [Liechty KW, et al. 1999], and glial cell–derived neurotrophic factor presented 
abnormal expression in epithelial cells lining CCAM cysts. Jancelewicz et al., analyzed gene 
expression from laser dissected epithelium and mesenchyme of human fetal and postnatal CCAM. 
They demonstrated that markers of early lung development, such as Hoxb5 and TTF1, are 
overexpressed in fetal CCAM. They also demonstrated that FGF9 was overexpressed, however a 
decrease in FGF7 and no altered expression of FGF10 and FGFR2 [Jancelewicz T, et al. 2008]. 
Besides, increased proliferation and decreased apoptosis were also verified in CCAM specimens 
[Cass DL, et al. 1998]. All these data, strongly suggest a focal arrest in lung maturation during the 
fetal period. However, these studies have a common major limitation, which is that the analysis was 
performed in CCAM specimens that were surgically resected, analysis of which is unlikely to reveal 
the initial inciting events.  Previous studies in transgenic murine models, where heterotopic 
overexpression of FGF7 [Simonet WS, et al. 1995] and FGF10 [Clark JC, et al. 2001], and orthotopic 
overexpression of FGF9 [White AC, et al. 2006] resulted in marked perturbations of lung 
morphogenesis, suggesting that these factors might be implicated in the development of 
adenomatoid malformations. Again, it is unknown whether anomalous overexpression of genes such 
as FGF9 represents causation or a global delay in differentiation. 
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In our study, we have been able to evaluate in a prospective fashion the formation of CCAM-like 
malformations in response to overexpression of FGF10 in the mesenchymal compartment of the 
developing lung. We have demonstrated that transient overexpression of a single gene in a focal 
area of the lung is sufficient to reproduce the spectrum of gross and histologic features of human 
CCAM in a rat model. The striking similarity of these lesions to those seen in human CCAM strongly 
implicates mesenchymal overexpression of FGF10 in the initial events invoking CCAM formation. 
Our data thus far support FGF10 overexpression as the most important mechanistic component of 
CCAM formation. However, the identity of the primary mesenchymal perturbation that induces 
FGF10 over-expression remains to be determined.    
We have developed a powerfull tool for lung development modulation early in gestation that 
specifically targets the mesenchymal compartment. Despite not being able to induce lung growth, we 
contribute to unveil the mechanism underlying the formation of CCAM, and possibly to establish an 
experimental animal model for this disease. The selection of other growth or transcription factors and 
the application of the intrapulmonary fetal gene transfer methodology to murine models of human 
diseases, opens the perspectives for future pre-clinical studies.      
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Main Conclusions 
 
1. We report for the first time, the feasibility of using ultrasound biomicroscopy to perform in utero 
intrapulmonary injections in rats during pseudoglandular stage of lung development. Both adenoviral 
and lentiviral vectors efficiently transduced lung parenchyma, although different expression patterns 
were observed following injection. Adenoviral vector expression was transient and started very 
quickly after its injection, whereas lentiviral vector expression was relatively delayed and persisted 
through seven days after birth, the time-point that we analyzed.  
 
2. The possibility of targeting the lung during the pseudoglandular stage may present unique 
experimental and ultimately perhaps clinical opportunities. Gene transfer during this period has the 
potential to modulate major key elements of pulmonary branching with minimal effects on immune 
responses. The ability to achieve gene transfer by direct intrapulmonary injection in a rat model 
provides a novel tool for exploration of potential therapeutic strategies for lung diseases. 
 
3. Pulmonary interstitial cells, rather than alveolar or airway epithelial cells, or vascular endothelial 
cells, were selectively transduced both by adenoviral and lentiviral vectors. This was the first 
observation of this pattern of parenchymal expression following prenatal lung gene transfer. The 
ability to target mesenchymal compartment raises the possibility to modulate mesenchymal-factors 
involved in  lung development with a more discrete and physiological approach.   
 
4. FGF10 over-expression in the lung mesenchyme during pseudoglandular stage by 
intraparenchymal gene transfer did not induced lung growth. Instead, there was a disturbance of 
pulmonary morphogenesis with appearance of localized cystic lung malformations. The type of 
malformation observed was developmental stage and location dependent, with the spectrum ranging 
from macrocystic malformations lined by predominantly bronchial epithelium, to microcystic 
malformations lined by predominantly alveolar epithelium.  
 
5. We have demonstrated prospectively that transient over-expression of a single gene in a focal 
area of the lung is sufficient to reproduce the spectrum of gross and histological features of human 
CCAM in a rat model. The striking similarity of these lesions to those seen in human CCAM strongly 
implicates mesenchymal over-expression of FGF10 in the initial events invoking CCAM formation.  
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